Document:

EX-10.3

 Exhibit 10.3 

EXECUTION VERSION 
 INVESTMENT
AGREEMENT 
 dated as of June 18, 2020 

by and between 
 ATHENE LIFE RE
LTD. 
 and 
 BROOKE (HOLDCO1)
INC. 
  

  

 TABLE OF CONTENTS 

 

							
	ARTICLE I DEFINITIONS	  	 	1	 
	 Section 1.01
	  	Certain Defined Terms	  	 	1	 
		
	ARTICLE II PURCHASE AND SALE	  	 	9	 
	 Section 2.01
	  	Purchase and Sale of the Purchased Shares	  	 	9	 
	 Section 2.02
	  	Purchase Price	  	 	10	 
	 Section 2.03
	  	Post-Closing Purchase Price True-Up	  	 	10	 
	 Section 2.04
	  	Authorization of Shares	  	 	10	 
		
	ARTICLE III THE CLOSING	  	 	10	 
	 Section 3.01
	  	Closing	  	 	10	 
	 Section 3.02
	  	Share Purchase Closing Deliveries	  	 	11	 
		
	ARTICLE IV REPRESENTATIONS AND WARRANTIES REGARDING THE GROUP COMPANIES	  	 	12	 
	 Section 4.01
	  	Incorporation and Authority	  	 	12	 
	 Section 4.02
	  	No Conflict	  	 	13	 
	 Section 4.03
	  	Consents and Approvals	  	 	13	 
	 Section 4.04
	  	Capital Structure of the Issuer	  	 	13	 
	 Section 4.05
	  	Capital Structure of the Group Companies	  	 	14	 
	 Section 4.06
	  	Financial Statements; Absence of Undisclosed Liabilities	  	 	15	 
	 Section 4.07
	  	Absence of Certain Changes	  	 	17	 
	 Section 4.08
	  	Absence of Litigation	  	 	17	 
	 Section 4.09
	  	Compliance with Laws	  	 	17	 
	 Section 4.10
	  	Taxes	  	 	18	 
	 Section 4.11
	  	Tax Treatment of Insurance Contracts	  	 	18	 
	 Section 4.12
	  	Brokers	  	 	19	 
	 Section 4.13
	  	Governmental Licenses and Permits	  	 	19	 
	 Section 4.14
	  	Material Contracts	  	 	19	 
	 Section 4.15
	  	NO OTHER REPRESENTATIONS OR WARRANTIES	  	 	20	 
		
	ARTICLE V REPRESENTATIONS AND WARRANTIES REGARDING THE BUYER	  	 	21	 
	 Section 5.01
	  	Incorporation and Authority of the Buyer	  	 	21	 
	 Section 5.02
	  	No Conflict	  	 	21	 
	 Section 5.03
	  	Consents and Approvals	  	 	22	 
	 Section 5.04
	  	Absence of Litigation	  	 	22	 
	 Section 5.05
	  	Compliance with Law	  	 	22	 
	 Section 5.06
	  	Securities Matters	  	 	22	 
	 Section 5.07
	  	Financial Ability	  	 	23	 
	 Section 5.08
	  	Investigation	  	 	23	 
	 Section 5.09
	  	Brokers	  	 	23	 
	 Section 5.10
	  	No Inducement or Reliance; Independent Assessment	  	 	23	 
		
	ARTICLE VI ACTIONS PRIOR TO THE CLOSING DATE	  	 	24	 
	 Section 6.01
	  	Conduct of Business Prior to the Closing	  	 	24	 

  
 i 

  

							
	 Section 6.02
	  	Access to Information	  	 	25	 
	 Section 6.03
	  	Reasonable Best Efforts; Consents	  	 	25	 
	 Section 6.04
	  	Closing Deliverables	  	 	28	 
	 Section 6.05
	  	Restructuring	  	 	28	 
		
	 ARTICLE VII ADDITIONAL AGREEMENTS
	  	 	28	 
	 Section 7.01
	  	Confidentiality	  	 	28	 
	 Section 7.02
	  	Further Action	  	 	29	 
	 Section 7.03
	  	Standstill	  	 	29	 
	 Section 7.04
	  	Solicitation	  	 	30	 
		
	 ARTICLE VIII CONDITIONS TO CLOSING AND RELATED MATTERS
	  	 	30	 
	 Section 8.01
	  	Conditions to Obligations of the Issuer and the Buyer	  	 	30	 
	 Section 8.02
	  	Conditions to Obligations of the Issuer	  	 	30	 
	 Section 8.03
	  	Conditions to Obligations of the Buyer	  	 	31	 
		
	 ARTICLE IX SURVIVAL; INDEMNIFICATION; CERTAIN REMEDIES
	  	 	32	 
	 Section 9.01
	  	Survival	  	 	32	 
	 Section 9.02
	  	Indemnification by the Issuer	  	 	32	 
	 Section 9.03
	  	Indemnification by the Buyer	  	 	33	 
	 Section 9.04
	  	Claims Procedure	  	 	33	 
	 Section 9.05
	  	Payment	  	 	35	 
	 Section 9.06
	  	Treatment of Indemnification Payments	  	 	35	 
	 Section 9.07
	  	Provisions	  	 	35	 
	 Section 9.08
	  	Exclusive Remedies	  	 	35	 
	 Section 9.09
	  	Damages	  	 	36	 
	 Section 9.10
	  	Right to Recover	  	 	36	 
	 Section 9.11
	  	Double Claims	  	 	37	 
		
	 ARTICLE X TERMINATION AND WAIVER
	  	 	37	 
	 Section 10.01
	  	Termination	  	 	37	 
	 Section 10.02
	  	Notice of Termination	  	 	38	 
	 Section 10.03
	  	Effect of Termination	  	 	38	 
	 Section 10.04
	  	Extension; Waiver	  	 	38	 
		
	 ARTICLE XI GENERAL PROVISIONS
	  	 	38	 
	 Section 11.01
	  	Expenses	  	 	38	 
	 Section 11.02
	  	Notices	  	 	38	 
	 Section 11.03
	  	Public Announcements	  	 	39	 
	 Section 11.04
	  	Severability	  	 	39	 
	 Section 11.05
	  	Entire Agreement	  	 	40	 
	 Section 11.06
	  	Assignment	  	 	40	 
	 Section 11.07
	  	No Third-Party Beneficiaries	  	 	40	 
	 Section 11.08
	  	Amendment	  	 	40	 
	 Section 11.09
	  	Schedules	  	 	40	 
	 Section 11.10
	  	Submission to Jurisdiction	  	 	41	 
	 Section 11.11
	  	Governing Law	  	 	41	 

  
 ii 

  

							
	 Section 11.12
	  	Waiver of Jury Trial	  	 	41	 
	 Section 11.13
	  	Specific Performance	  	 	41	 
	 Section 11.14
	  	Waivers	  	 	42	 
	 Section 11.15
	  	Rules of Construction	  	 	42	 
	 Section 11.16
	  	Reserves	  	 	43	 
	 Section 11.17
	  	Counterparts	  	 	43	 

  

			
	SCHEDULES	 	
		
	Schedule 1.01(a)	 	 Issuer Knowledge Persons

	Schedule 1.01(b)	 	 Buyer Knowledge Persons

	Schedule 5.03	 	 Buyer Consents and Approvals

	Schedule 6.03(i)	 	 Third-Party Consents

	Schedule 8.01(a)	 	 Governmental Approvals

	Schedule 11.03	 	 Initial Press Release

		
	EXHIBITS	 	
		
	Exhibit A	 	 Form of Registration Rights Agreement

	Exhibit B	 	 Form of Stockholders Agreement

	Exhibit C	 	 Form of Amended and Restated Certificate of Incorporation

  

  
 iii 

  

 This INVESTMENT AGREEMENT (including all schedules, exhibits and amendments hereto, this
“Agreement”), dated as of June 18, 2020, is made by and between Athene Life Re Ltd., a Bermuda Class E insurer under the Bermuda Insurance Act 1978 (the “Buyer”), and Brooke (Holdco1) Inc., a Delaware
corporation (the “Issuer”). 
 PRELIMINARY STATEMENTS 

A.     Upon the terms and subject to the conditions set forth in this Agreement, the Issuer desires to issue and sell to
the Buyer, and the Buyer desires to subscribe for and purchase from the Issuer, the Purchased Shares (as defined herein); and 

B.     Concurrently with the execution of this Agreement, the Cedant (as defined herein), a Subsidiary of the Issuer, and
the Buyer, entered into a reinsurance agreement (the “Reinsurance Agreement”) pursuant to which the Cedant has ceded to the Buyer and the Buyer accepted and reinsured certain reinsured liabilities on a combined funds withheld and
coinsurance basis. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties to this Agreement
agree as follows: 
 ARTICLE I 

DEFINITIONS 
 
Section 1.01    Certain Defined Terms. Capitalized terms used in this Agreement have the meanings specified or referred to in this Section 1.01. 

“Action” means any claim, action, suit, litigation, arbitration, examination, investigation or proceeding by or before any
Governmental Authority or arbitrator or arbitration panel or similar Person or body. 
 “Adjusted Share Price” shall have
the meaning set forth in Section 2.03(a). 
 “Affiliate” means, with respect to any specified
Person, any other Person that, at the time of determination, directly or indirectly through one or more intermediaries, Controls, is Controlled by or is under common Control with such specified Person; provided, that in no event shall
(a) any pooled investment vehicle, fund, managed account or other client to which Apollo Global Management, Inc. or any of its respective Affiliates or Subsidiaries provides investment advice or otherwise serves in a fiduciary capacity
or (b) any portfolio company in which the entities described in clause (a) directly or indirectly hold investments be deemed an Affiliate of the Buyer. For the avoidance of doubt, the Issuer and the Buyer shall not be deemed to be
“Affiliates” of one another for purposes of this definition. 
 “Agreement” shall have the meaning set forth in
the preamble hereto. 
 “Amended and Restated Certificate of Incorporation” shall have the meaning set forth in
Section 2.04. 

  

 “Annual SAP Financial Statements” shall have the meaning set forth in
Section 4.06(b). 
 “Audited Financial Statements” shall have the meaning set forth in
Section 4.06(a). 
 “Business” means the business of the Issuer and its Subsidiaries as conducted
as of the date hereof. 
 “Business Day” means any day that is not a Saturday, Sunday or other day on which commercial
banks in Lansing, Michigan or New York, New York are required or authorized by Law to remain closed. 
 “Buyer” shall have
the meaning set forth in the preamble hereto. 
 “Buyer Indemnitee” means the Buyer, each of its Subsidiaries and
Affiliates, and its and their respective officers, directors, employees, agents, successors and assigns. 
 “Buyer Liens”
means any Liens arising as a result of any agreement of, or any Governmental Order binding on, or any condition applicable to, or otherwise resulting from any facts or circumstances relating to, the Buyer or its designated assignee(s) hereunder or
any of their respective Affiliates. 
 “Buyer Material Adverse Effect” means a material impairment or delay of the ability
of the Buyer to perform its material obligations under this Agreement, including consummation of the transactions contemplated hereby. 

“Capital Stock” means any capital stock of, or other type of equity ownership interest in, as applicable, a Person. 

“Capital Stock Equivalents” means securities, options or rights directly or indirectly convertible into or exchangeable or
exercisable for Capital Stock. 
 “Cedant” means Jackson National Life Insurance Company, a Michigan life insurance
company. 
 “Class A Common Stock” means the Issuer’s Class A common stock, par value $0.01
per share, to be established pursuant to the Amended and Restated Certificate of Incorporation. 
 “Class B
Common Stock” means the Issuer’s Class B common stock, par value $0.01 per share, to be established pursuant to the Amended and Restated Certificate of Incorporation. 

“Closing” shall have the meaning set forth in Section 3.01. 

“Closing Date” shall have the meaning set forth in Section 3.01. 

  
 2 

  

 “Closing Share Price” means $5,000,000 per share of Common Stock. 

“Code” means the United States Internal Revenue Code of 1986. 

“Common Stock” means (i) prior to the filing of the Amended and Restated Certificate of Incorporation, the common
stock of the Issuer, par value $125.00 per share and (ii) after the filing of the Amended and Restated Certificate of Incorporation, the Class A Common Stock and the Class B Common Stock. 

“Confidentiality Agreement” shall have the meaning set forth in Section 7.01(a). 

“Contagion Event” means the outbreak and ongoing effects of any contagious disease, epidemic or pandemic (including COVID-19). 
 “Control” means, with respect to any Person, the power to direct or cause
the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise. The terms “Controlled,” “Controlled by,” “under common Control
with” and “Controlling” shall have correlative meanings. 
 “Disclosure Schedule” means the
disclosure schedule dated as of the date hereof delivered by the Issuer to the Buyer in connection with the execution and delivery of this Agreement. 

“Effective Time” shall have the meaning set forth in the Reinsurance Agreement. 

“Electronic Data Room” means the electronic data site titled “Project Star” established by Parent and maintained by
Intralinks in connection with the transactions contemplated by this Agreement to which the Buyer and its Representatives have access. 

“Financial Statements” means the GAAP Financial Statements and the SAP Financial Statements. 

“Fundamental Representations” means the representations and warranties of the Issuer contained in
Section 4.01(a), Section 4.01(d), Section 4.04, Section 4.05(e), Section 4.07(ii) and
Section 4.12. 
 “GAAP” means the accounting principles and practices generally accepted in the
United States at the relevant time. 
 “GAAP Financial Statements” shall have the meaning set forth in
Section 4.06(a). 
 “Governmental Approval” means any consent, approval, license, permit, order,
qualification, authorization of, or registration, waiver or other action by, or any filing with or notification to, any Governmental Authority. 

“Governmental Authority” means any United States or non-United States federal, state
or local or any supra-national, political subdivision, governmental, legislative, tax, regulatory or administrative authority, instrumentality, agency, body or commission, self-regulatory organization or any court, tribunal, or judicial or arbitral
body. 

  
 3 

  

 “Governmental Order” means any binding and enforceable order, writ,
judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
 “Group
Companies” means the Issuer and all its Subsidiaries. 
 “HSR Act” shall mean the Hart-Scott-Rodino Antitrust
Improvements Act of 1976. 
 “Indemnified Party” means, as the context requires, (a) a Buyer Indemnitee as it
may be entitled to any indemnification payment from the Issuer pursuant to Section 9.02, or (b) an Issuer Indemnitee as it may be entitled to any indemnification payment from the Buyer pursuant to
Section 9.03. 
 “Indemnifying Party” means, as the context
requires, (a) the Issuer as it may have Liability for any indemnification payment to a Buyer Indemnitee pursuant to Section 9.02, or (b) the Buyer as it may have Liability for any indemnification
payment to an Issuer Indemnitee pursuant to Section 9.03.  
 “Initial
Closing” shall have the meaning set forth in Section 6.05. 
 “Insurance Companies”
means, collectively, the Cedant, Brooke Life Insurance Company, Jackson National Life Insurance Company of New York, Squire Reassurance Company II, Inc., Jackson National Life (Bermuda) Ltd. and VFL International Life Company SPC, Ltd. and, each of
them, an “Insurance Company”. 
 “Insurance Contracts” means the insurance or annuity policies and
contracts, guaranteed investment contracts and funding agreements, together with all binders, slips, certificates, endorsements and riders thereto, issued, assumed, written, underwritten or entered into by any Insurance Company (or any entity to
which such Insurance Company is a successor in interest) prior to the Closing. 
 “Interim Financial Statements” shall have
the meaning set forth in Section 4.06(a). 
 “Intermediate Parent” means Prudential (US Holdco 1)
Limited. 
 “IPO” shall have the meaning set forth in the Stockholders Agreement. 

“Issuer” shall have the meaning set forth in the preamble hereto. 

“Issuer Indemnitee” means the Issuer, each of its Subsidiaries and Affiliates, and its and their respective officers,
directors, employees, agents, successors and assigns. 

  
 4 

  

 “Issuer Party” means each Affiliate of the Issuer that is, or is
contemplated by this Agreement to become at the Closing, a party to one or more Transaction Agreements. 
 “Knowledge”
means: (a) in the case of the Issuer, the actual knowledge of those Persons listed in Schedule 1.01(a), after reasonable inquiry by each such individual of such individual’s direct reports, and
(b) in the case of the Buyer, the actual knowledge of those Persons listed in Schedule 1.01(b), after reasonable inquiry by each such individual of such individual’s direct reports. 

“Law” means any United States or non-United States federal, state or local statute,
law, ordinance, regulation, code, Governmental Order or other requirement or rule of law. 
 “Liabilities” means any and
all debts, liabilities, commitments or obligations, whether direct or indirect, accrued or fixed, known or unknown, absolute or contingent, matured or unmatured, or determined or determinable, whether arising in the past, present or future. 

“Lien” means any mortgage, deed of trust, pledge, hypothecation, security interest or other similar encumbrance or lien. 

“Losses” means any damages, losses, claims, demands, actions, suits, proceedings, payments, judgments, Taxes and out-of-pocket costs and expenses (including reasonable legal fees) and costs and expenses of investigating or contesting any of the foregoing. 

“Material Adverse Effect” means (a) a material adverse effect on the business, assets, liabilities, condition
(financial or otherwise), or results of operations of the Group Companies, taken as a whole; provided that no fact, circumstance, change or effect arising out of or resulting from any of the following, either alone or in combination, shall
constitute or be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur: (i) the United States or global economy or capital or financial markets, including changes in
interest or exchange rates or changes in equity markets and related changes in the statutory or fair market value of the investment assets of the Group Companies, (ii) political conditions generally and any natural disasters,
hostilities, acts of war, sabotage, terrorism or military actions, (iii) any Contagion Event, or any worsening of such matters existing as of the date hereof, or any declaration of martial law, quarantine or similar directive, policy or
guidance or other action by any Governmental Authority in response thereto, (iv) any occurrence or condition generally affecting participants in the life insurance and annuity industries in the United States, (v) the
negotiation, execution and delivery of, or compliance with the terms of, or any action required to be taken or omitted by this Agreement, or the announcement of, or consummation of, any of the transactions contemplated hereby, and the identity or
facts related to the Buyer (including (A) effects related to compliance with the covenants contained herein or the failure to take any action as a result of any restrictions or prohibitions set forth herein and (B) any effect
caused by (I) shortfalls or declines in revenue, margins or profitability, (II) loss of, or disruption in, any customer, supplier and/or vendor relationships or (III) loss of personnel) (provided, that this
clause (v) shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address, as applicable, the consequences resulting from the execution and delivery of this

  
 5 

  

 
Agreement, the pendency or consummation of this Agreement or any of the Transaction Agreements), (vi) any changes or prospective changes in Law, GAAP, SAP or the enforcement or
interpretation thereof, (vii) any action taken by the Buyer or its Affiliates, or taken by any of the Issuer or any of its Affiliates at the request of the Buyer or with the Buyer’s prior consent or any action for which the
Buyer’s consent is requested in good faith and in the ordinary course of business pursuant to Section 6.01 but is not taken because the Buyer withheld, conditioned or delayed its consent, (viii) any change
(or threatened change) in the credit, financial strength or other ratings (other than the underlying facts and circumstances that gave rise or contributed to any such change (or threatened change)) of any of the Group Companies or any of their
Affiliates, (ix) any failure by the Group Companies to achieve any earnings, premiums written or other financial projections or forecasts (other than the underlying facts and circumstances that may have given rise or contributed to such
failure), (x) any matter to the extent specifically reflected in any of the Financial Statements or (xi) any effect that is or would be reasonably likely to be cured by the Group Companies prior to the Closing; provided,
however, that, with respect to clauses (i), (ii), (iii), (iv) and (vi), such effect shall be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur solely to the extent
such effect, individually or in the aggregate, is disproportionately adverse with respect to the Group Companies as compared to other participants in the life insurance and annuity industries in the United States or (b) a material
impairment or delay of the ability of the Issuer to perform its material obligations under this Agreement, including consummation of the transactions contemplated hereby. 

“Material Contract” shall have the meaning set forth in Section 4.14(a). 

“Milliman” means Milliman, Inc. 

“Outside Date” shall have the meaning set forth in Section 10.01(b). 

“Parent” means Prudential plc. 

“Permits” shall have the meaning set forth in Section 4.13(a). 

“Permitted Liens” means each of the following: (a) Liens that secure debt that is reflected on the Financial
Statements, (b) Liens for Taxes, assessments or other governmental charges or levies that are not yet due or payable or that are being contested in good faith by appropriate proceedings, (c) statutory Liens of landlords and
Liens of carriers, warehousemen, mechanics, materialmen, repairmen and other similar Liens imposed by Law for amounts not yet due, (d) Liens incurred or deposits made to a Governmental Authority in connection with a governmental
authorization, registration, filing, license, permit or approval, (e) Liens incurred or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance or other types of social
security, (f) defects of title, easements, rights of way, covenants, restrictions and other similar Liens not materially interfering with the ordinary conduct of business, (g) Liens not created by a Group Company that affect
the underlying fee interest of any leased real property, (h) Liens incurred in the ordinary course of business securing obligations or Liabilities that are not individually or in the aggregate material to the relevant asset or property,
respectively, (i) zoning, building and other generally applicable land use restrictions, (j) Liens or other imperfections of title that do not materially interfere with the 

  
 6 

  

 
present use of the current use of the properties, assets or rights affected thereby, (k) Buyer Liens, (l) limitations on the rights of any of the Group Companies under any
contract that are expressly set forth in such contract, (m) Liens arising under a conditional sales contract or equipment lease with a third party, (n) Liens incurred in the ordinary course of business since the date of the
most recent Financial Statements, (o) Liens that are disclosed in any section of the Disclosure Schedule, (p) Liens arising from any act of the Buyer or any of its Affiliates (with respect to an asset of any of the Issuer or
its Affiliates), (q) Liens created in connection with investment transactions, including broker liens, securities lending transactions and repurchase agreements and Federal Home Loan Bank of Indianapolis advances, (r) Liens
created in connection with hedging transactions and (s) nonexclusive licenses to intellectual property executed in the ordinary course of business. 

“Permitted Transferee” shall have the meaning set forth in the Stockholders Agreement. 

“Person” means any natural person, general or limited partnership, corporation, limited liability company, limited liability
partnership, firm, association or organization or other legal entity. 
 “Product Tax Rules” means the Tax Laws with
respect to (a) the requirements for the Insurance Contracts to qualify for certain Tax treatment and (b) the Tax reporting and withholding applicable to the Insurance Contracts. For the avoidance of doubt, “Product Tax
Rules” include sections 72, 101, 401 through 409A, 412, 415, 417, 457, 817, 7702, 7702A and 7702B of the Code and the Treasury Regulations promulgated thereunder, and related administrative guidance and judicial interpretations. 

“Protected Period” means the period beginning on the date hereof and ending on the date that is the earlier to occur of
(a) the first anniversary of the Closing Date and (b) the consummation of an IPO. 
 “Purchased
Shares” shall have the meaning set forth in Section 2.01. 
 “Purchase Price” shall have
the meaning set forth in Section 2.02. 
 “Registration Rights Agreement” means the Registration
Rights Agreement in substantially the form attached as Exhibit A hereto. 
 “Reinsurance Agreement” shall have the
meaning set forth in the recitals hereto. 
 “Representative” of a Person means the directors, officers, employees,
advisors, agents, stockholders, consultants, independent accountants, investment bankers, counsel or other representatives of such Person and of such Person’s Affiliates. 

“SAP” means the statutory accounting principles and practices prescribed or permitted by the Governmental Authority with
principal responsibility for regulating an Insurance Company as in effect at the relevant time. 
 “SAP Financial
Statements” shall have the meaning set forth in Section 4.06(b). 

  
 7 

  

 “Securities Act” means the Securities Act of 1933. 

“Stockholders Agreement” means the Stockholders Agreement in substantially the form attached as
Exhibit B hereto. 
 “Subject Transaction” means (a) an issuance or sale by any Group
Company of any Capital Stock or Capital Stock Equivalents in any individual transaction (or series of related transactions) or (b) a direct or indirect sale by Parent or any of its Subsidiaries (other than a Group Company) of any Capital
Stock or Capital Stock Equivalents of the Issuer or any of the Group Companies (including any derivative transaction the payments under which are determined with reference to the Capital Stock of the Issuer or any of the Group Companies or their
businesses or assets), in either case, during the Protected Period; provided, that no: (i) IPO or other similar transaction in which shares of Common Stock are issued in a public offering or publicly traded securities are
distributed to the stockholders of Parent, (ii) issuance or sale of Capital Stock Equivalents in connection with the transactions described in the foregoing clause (i), (iii) issuance pursuant to a compensatory equity
participation plan of the Issuer adopted in connection with an IPO, or (iv) issuance (or series of related issuances) or sale (or series of related sales) of Capital Stock or Capital Stock Equivalents for consideration in an aggregate
amount of less than $50 million shall be a “Subject Transaction” hereunder. In the event that a Subject Transaction involves the issuance or sale of Capital Stock Equivalents, the applicable seller or issuer thereof shall be deemed to
have issued at that time a number of shares of Capital Stock equal to the maximum number of shares of Capital Stock that are or may become issuable upon exercise or conversion of such Capital Stock Equivalents (whether or not the same are then
currently exercisable) for consideration equal to (A) the aggregate consideration received by the applicable seller or issuer in connection with the issuance or sale of such Capital Stock Equivalents plus (B) the minimum
amount of such consideration receivable by the applicable seller or issuer in connection with the exercise or conversion of such Capital Stock Equivalents. Any non-cash consideration received in connection
with a Subject Transaction shall be valued at fair market value as determined by the board of directors of the Issuer in good faith. In the case of a derivative transaction, the purchase price shall be the aggregate payments (if any) received by
Parent or its Affiliates in connection with entering into the derivative transaction plus (or minus) the amount of the early termination payment that would be payable to (or from) Parent or its Affiliate upon the early termination of such derivative
at such time in accordance with its terms and the number of shares purchased shall be the notional amount of shares of Capital Stock subject to such transaction (or, where the value is calculated with reference to items other than a number of shares
of Capital Stock, the proportion of the outstanding shares of Capital Stock represented by such reference items). 

“Subsidiary” of any Person means any corporation, general or limited partnership, joint venture, limited liability company,
limited liability partnership or other Person that is a legal entity, trust or estate of which (or in which) at the time of determination (a) the issued and outstanding Capital Stock having ordinary voting power to elect a majority of
the board of directors (or a majority of another body performing similar functions) of such corporation or other Person (irrespective of whether at the time Capital Stock of any other class or classes of such corporation or other Person shall or
might have voting power upon the occurrence of any contingency), (b) more than fifty percent (50%) of the interest in the capital or profits of such partnership, joint venture or limited liability company or (c) more than
fifty percent (50%) of the beneficial interest in such trust or estate, is directly or indirectly owned by such Person. 

  
 8 

  

 “Tax” or “Taxes” means all income, premium, alternative
minimum, accumulated earnings, personal holding company, capital stock, gross receipts, value added, registration, premium, retaliatory, customs duties, severance, environmental, real property, personal property, ad valorem, occupancy, license,
occupation, social security, disability, unemployment, workers’ compensation, estimated, excise, gross receipts, ad valorem, sales, use, employment, franchise, profits, gains, transfer, payroll, stamp taxes or any other taxes (whether payable
directly or by withholding) imposed by any Tax Authority, in each case, together with any interest and any penalties thereon or additional amounts with respect thereto; provided, that any guarantee fund assessment or escheatment obligation
shall not be treated as a Tax. 
 “Tax Authority” means any Governmental Authority having jurisdiction over the assessment,
determination, collection or imposition of any Tax. 
 “Tax Returns” means all returns, reports or similar statements and
claims for refunds (including elections, declarations, disclosures, schedules, estimates and information returns) required to be supplied to a Tax Authority relating to Taxes and, in each case, any amendments thereto. 

“Third Party Claim” shall have the meaning set forth in Section 9.04(a). 

“Third-Party Consent” means any approval, authorization, consent, license or permission of, or waiver or other action by, or
notification to, any third party (other than a Governmental Authority or an Affiliate of either of the Issuer or the Buyer) required in connection with the transactions contemplated by the Transaction Agreements. 

“Transaction Agreements” means this Agreement, the Stockholders Agreement and the Registration Rights Agreement. 

“True-up Issuance Date” shall have the meaning set forth in
Section 2.03(a). 
 “True-up Shares” means a number of
shares of authorized, validly-issued, fully-paid and non-assessable shares of Class B Common Stock, free and clear of any Liens other than Buyer Liens and restrictions arising under applicable securities
Laws, equal to the difference between (a) the Purchase Price divided by the Adjusted Share Price and (b) the Purchase Price divided by the Closing Share Price, as adjusted to reflect any stock splits, stock
dividends or other similar events occurring prior to the True-up Issuance Date. 
 ARTICLE II

 PURCHASE AND SALE 

Section 2.01    Purchase and Sale of the Purchased
Shares. On the terms and subject to the conditions set forth in this Agreement, at the Closing, in consideration of payment of the Purchase Price as set forth in Section 2.02 below, the Issuer shall issue and sell to
the Buyer, and the Buyer shall purchase from the Issuer, free and clear of any Liens other than Buyer Liens and restrictions arising under applicable securities Laws and the Transaction Agreements, eighty-seven (87) shares of Class A
Common Stock and thirteen (13) shares of Class B Common Stock (collectively, the “Purchased Shares”). 

  
 9 

  

Section 2.02    Purchase Price. The purchase price
payable by the Buyer to the Issuer (or another entity designated in writing by the Issuer) for the Purchased Shares shall be the amount in immediately available funds of $500,000,000 (the “Purchase Price”). The Purchase Price shall
be payable at Closing as set forth below in Section 3.02. 
 Section 2.03    Post-Closing Purchase Price True-Up. 
 
(a)    In the event that: (i) a Subject Transaction is consummated (A) at any time during the Protected Period or (B) after the Protected Period pursuant to a
definitive agreement negotiated or executed prior to the expiration of the Protected Period; and (ii) the price per share of Common Stock paid in such Subject Transaction (as adjusted to reflect any stock splits, stock dividends or other
similar events occurring prior to the consummation of such Subject Transaction, the “Adjusted Share Price”) is less than the Closing Share Price (as adjusted to reflect any stock splits, stock dividends or other similar events
following the Closing Date), then, within five (5) Business Days of the consummation of such Subject Transaction (the “True-up Issuance Date”), the Issuer shall issue to the Buyer, and
the Buyer shall acquire from the Issuer, a number of shares of Class B Common Stock equal to the True-Up Shares. Except in connection with an additional issuance or sale of Common Stock or Capital Stock
Equivalents that would constitute part of the same Subject Transaction for which the True-up Shares are issued, upon issuance of the True-up Shares in accordance with
this Section 2.03, no further adjustments shall be made in the event of any separate Subject Transactions consummated after the True-up Issuance Date. 

(b)    On the True-up Issuance Date, the Issuer shall deliver, or cause to be
delivered, to the Buyer one or more stock certificates evidencing the True-up Shares issued in the name of the Buyer or such other Permitted Transferee as Buyer may request. 

(c)    For Tax purposes, the issuance of any additional shares of Class B Common Stock pursuant to this
Section 2.03 shall be treated as an adjustment to the number of Purchased Shares issued to the Buyer at the Closing. 

Section 2.04    Authorization of Shares. Prior to the Closing, the Issuer shall
establish the Class A Common Stock and the Class B Common Stock, and authorize the issuance of up to one thousand (1,000) shares of Class A Common Stock and one thousand (1,000) shares of Class B Common Stock by filing an Amended
and Restated Certificate of Incorporation in the form attached hereto as Exhibit C (the “Amended and Restated Certificate of Incorporation”) with the Secretary of State of the State of Delaware. 

ARTICLE III 
 THE
CLOSING 
 Section 3.01    Closing. The closing of the purchase and sale of
the Purchased Shares contemplated by this Agreement (the “Closing”) shall take place at 10:00 a.m., New York City time, at the offices of Debevoise & Plimpton LLP, 919 Third Avenue, New York, New York 10022 (or such other
place as the Issuer and the Buyer may agree in writing) on the third 

  
 10 

  

 
(3rd) Business Day after the satisfaction or waiver of each of the conditions set forth in Article VIII has occurred (other than those conditions that by their terms are
to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at the Closing), or such other date as mutually agreed by the Issuer and the Buyer. The date on which the Closing takes place shall be the “Closing
Date”. 
 Section 3.02    Share Purchase Closing Deliveries. 

(a)    At the Closing, the Buyer shall deliver, or cause to be delivered, to the Issuer: 

(i)    payment, by wire transfer to a bank account designated in writing by the Issuer (such designation to
be made at least two (2) Business Days before the Closing Date), of immediately available funds in an amount equal to the Purchase Price; 

(ii)    the Stockholders Agreement, duly executed by the Buyer; 

(iii)    the Registration Rights Agreement, duly executed by the Buyer; 

(iv)    the certificate referred to in Section 8.02(d); and 

(v)    a copy of the resolutions of the board of directors of the Buyer authorizing the execution and
delivery of this Agreement and the other Transaction Agreements and approval of the transactions contemplated hereby and thereby. 

(b)    At the Closing, the Issuer shall deliver, or cause to be delivered, to the Buyer: 

(i)    one or more stock certificates evidencing the Purchased Shares issued in the name of the Buyer; 

(ii)    the Stockholders Agreement, duly executed by the Issuer and Intermediate Parent; 

(iii)    the Registration Rights Agreement, duly executed by the Issuer; 

(iv)    the certificate referred to in Section 8.03(d); and 

(v)    a copy of (A) the resolutions of the board of directors of the Issuer authorizing the
execution and delivery of this Agreement and the other Transaction Agreements and approval of the transactions contemplated hereby and thereby, including the filing of the Amended and Restated Certificate of Incorporation and (B) the
written consent of Intermediate Parent adopting the Amended and Restated Certificate of Incorporation and approving the filing of the same. 

  
 11 

  

 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES REGARDING 

THE GROUP COMPANIES 

Subject to and as qualified by the matters set forth in the Disclosure Schedule pursuant to Section 11.09, the
Issuer hereby represents and warrants to the Buyer as follows as of the date hereof and as of the Closing Date (except for such representations and warranties which address matters only as of a specific date, which representations and warranties
shall be true and correct as of such specific date): 
 Section 4.01    Incorporation and Authority. 

(a)    The Issuer (i) is a corporation duly incorporated, validly existing and in
good standing under the Laws of the State of Delaware, (ii) is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the character of its owned, operated or leased properties or the
nature of its activities makes such qualification necessary and (iii) has the requisite corporate power and authority to operate its business as now conducted, except where the failures to be so qualified, individually or in the
aggregate, would not reasonably be expected to have a Material Adverse Effect. 
 (b)    Each of the Group Companies and
each Issuer Party (i) is a corporation or other organization duly incorporated or organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation or organization, (ii) is duly qualified as
a foreign corporation or other organization to do business and is in good standing in each jurisdiction where the character of its owned, operated or leased properties or the nature of its activities makes such qualification necessary and
(iii) has the requisite corporate or other power and authority to operate its business as now conducted, except where the failures to be so qualified, individually or in the aggregate, would not reasonably be expected to have a Material
Adverse Effect. 
 (c)    The Issuer has made available to the Buyer copies of the organizational documents of the Group
Companies, in each case as amended and in effect as of the date hereof. 
 (d)    The
Issuer and each Issuer Party has all requisite corporate or other power to enter into, consummate the transactions contemplated by, and carry out its obligations under, this Agreement and the other Transaction Agreements to which the Issuer or such
Issuer Party is a party. The execution and delivery by each of the Issuer of this Agreement and the other Transaction Agreements to which it is or will be a party, and the consummation by the Issuer and each Issuer Party of the transactions
contemplated by, and the performance by the Issuer and each Issuer Party of its obligations under, this Agreement and the other Transaction Agreements to which it is or will be a party have been duly authorized by all requisite corporate action on
the part of the Issuer and each Issuer Party, as applicable. This Agreement and the other Transaction Agreements to which it is or will be a party has been duly executed and delivered by the Issuer and each Issuer Party, as applicable, and this
Agreement and the other Transaction Agreements to which it is or will be a party (assuming due authorization, execution and delivery by the Buyer) constitute the legal, valid and binding obligation of the Issuer and each Issuer Party, as applicable,
enforceable against each of them in accordance with its terms, subject to the effect of any applicable bankruptcy, reorganization, insolvency, moratorium, rehabilitation, liquidation, fraudulent conveyance or similar Laws relating to or affecting
creditors’ rights generally and subject, as to enforceability, to the effect of general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). 

  
 12 

  

Section 4.02    No Conflict. Provided that all
consents, approvals, authorizations and other actions described in Section 4.03 have been obtained or taken, except as set forth in Section 4.02 of the Disclosure Schedule and except as may result
from any facts or circumstances solely relating to the Buyer or its Affiliates (as opposed to any other third party), the execution, delivery and performance by the Issuer and each Issuer Party of, and the consummation by each of them of the
transactions contemplated by, this Agreement and the other Transaction Agreements to which it is or will be a party do not (a) violate or conflict with the organizational documents of the Issuer, any Issuer Party or any Group Company,
(b) violate or conflict with any Law or other Governmental Order applicable to the Issuer, any Issuer Party or any Group Company or by which any of them or any of their respective properties or assets is bound or subject, or
(c) result in any breach of, or constitute a default (or event which, with the giving of notice or lapse of time, or both, would become a default) under, or give to any Person any rights of termination, acceleration, impairment,
alteration or cancellation of, or result in the creation of any Lien (other than a Permitted Lien) on any of the assets, rights or properties of the Issuer, any Issuer Party or any Group Company pursuant to, or result in any acceleration of
remedies, penalties or material increase or decrease in an amount payable or an obligation or benefit under, any material note, bond, mortgage, indenture or contract to which the Issuer, any Issuer Party or any Group Company is a party or which any
of such assets or properties is bound, other than, in the case of clauses (b) or (c), any such conflicts, violations, breaches, defaults, rights or Liens that, individually or in the aggregate, do not have, and would not reasonably be expected
to have, a Material Adverse Effect. 

Section 4.03    Consents and Approvals. Except as
set forth in Section 4.03 of the Disclosure Schedule or as may result from any facts or circumstances solely relating to the Buyer or its Affiliates (as opposed to any other third party), the execution and delivery by the
Issuer of this Agreement and the other Transaction Agreements to which it is or will be a party do not and will not, and the performance by the Issuer, the Issuer Parties and the Group Companies of, and the consummation by the Issuer, the Issuer
Parties and the Group Companies of the transactions contemplated by, this Agreement and the other Transaction Agreements to which it is or will be a party do not and will not require any Governmental Approval to be obtained or made by the Issuer,
any Issuer Party or any Group Company prior to the Closing, except for such Governmental Approvals, the failure of which to be obtained or made has not, and would not reasonably be expected to have, a Material Adverse Effect. 

Section 4.04    Capital Structure of the Issuer. 

(a)    The authorized Capital Stock of the Issuer consists of one thousand (1,000) shares of Common Stock, of which seven
hundred and thirty-four (734) are issued and outstanding as of the date of this Agreement. As of the Closing Date, the authorized Capital Stock of the Issuer will consist of two thousand (2,000) shares of Common Stock, including one thousand
(1,000) shares of Class A Common Stock and one thousand (1,000) shares of Class B Common Stock. 

(b)    Except as set forth in Section 4.04(a), there are no shares of Capital Stock of the
Issuer issued and outstanding. All of the outstanding shares of Capital Stock of the Issuer as of the date hereof have been duly authorized and validly issued, are fully paid and non-assessable and were not
issued in violation of any preemptive or subscription rights. As of the 

  
 13 

  

 
Closing Date, all of the outstanding shares of Capital Stock of the Issuer will be duly authorized and validly issued, fully paid and non-assessable and
will not be issued in violation of any preemptive or subscription rights. Except as expressly set forth in the Transaction Agreements, there are no, and at the Closing Date, there will be no, options, calls, warrants or convertible or exchangeable
securities, or conversion, preemptive, subscription or other rights, or agreements, arrangements or commitments, in any such case, obligating or which may obligate the Issuer to issue, sell, purchase, return or redeem (or establish a sinking fund
with respect to redemption) any Capital Stock of the Issuer or securities convertible into or exchangeable for any Capital Stock of the Issuer, and there are no, and at the Closing Date, there will be no, shares of Capital Stock of the Issuer
reserved for issuance for any purpose. There are no, and at the Closing Date, there will be no, capital appreciation rights, phantom stock plans, securities with participation rights or features or similar obligations or commitments of the Issuer.

 (c)    The issuance of the Purchased Shares to be issued pursuant to this Agreement has been, or prior to Closing
Date, will be, duly authorized by all necessary corporate action. When issued and paid for by the Buyer in accordance with this Agreement, the Purchased Shares will be validly issued, fully paid and
non-assessable, will not be subject to preemptive rights of any other shareholder of the Issuer, and will effectively vest in the Buyer good title to the Purchased Shares, free and clear of all Liens (other
than restrictions arising under applicable securities Laws or under the Transaction Agreements). The rights, privileges and preferences of the Purchased Shares will be as set forth in the Amended and Restated Certificate of Incorporation and the
Stockholders Agreement. 
 (d)    Subject to the accuracy of the representations and warranties made by the Buyer in
Section 5.06, the offer, sale and issuance of the Purchased Shares (i) have been and will be made in compliance with applicable exemptions from the registration and prospectus delivery requirements of the
Securities Act and (ii) will have been registered or qualified (or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable material blue sky laws. 

Section 4.05    Capital Structure of the Group Companies. 

(a)    Section 4.05(a) of the Disclosure Schedule sets forth (i) the authorized Capital Stock of
each Subsidiary of the Issuer and (ii) the number of shares of each class or series of Capital Stock of each of Subsidiary of the Issuer that are issued and outstanding, together with the registered holder thereof. Except as set forth in
Section 4.05(a) of the Disclosure Schedule, there are no shares of Capital Stock of Subsidiaries of the Issuer issued and outstanding. All of the outstanding shares of Capital Stock of the Subsidiaries of the Issuer have
been duly authorized and validly issued, are fully paid and nonassessable and were not issued in violation of any preemptive or subscription rights. There are no options, calls, warrants or convertible or exchangeable securities, or conversion,
preemptive, subscription or other rights, or agreements, arrangements or commitments, in any such case, obligating or which may obligate any of the Issuer, the Group Companies or any of their Affiliates to issue, sell, purchase, return or redeem (or
establish a sinking fund with respect to redemption) any Capital Stock of the Subsidiaries of the Issuer or securities convertible into or exchangeable for any Capital Stock of the Subsidiaries of the Issuer, and there are no shares of Capital Stock
of the Subsidiaries of the Issuer reserved for issuance for any purpose. There are no capital appreciation rights, phantom stock plans, securities with participation rights or features or similar obligations or commitments of any of the Subsidiaries
of the Issuer. 

  
 14 

  

 (b)    The Group Company that is listed as the registered holder of the
Capital Stock of each other Group Company as set forth in Section 4.05(a) of the Disclosure Schedule owns all of such outstanding Capital Stock of such Group Company, beneficially and of record and free and clear of all
Liens (other than restrictions arising under applicable securities Laws or under the Transaction Agreements). 

(c)    Except as expressly set forth in the Transaction Agreements, there are no voting trusts, stockholder agreements,
proxies or other rights or agreements in effect with respect to the voting, transfer or dividend rights of the Capital Stock of the Group Companies. 

(d)    Except as set forth in Section 4.05(a) of the Disclosure Schedule and investment assets
acquired in the ordinary course of business, the Group Companies have no Subsidiaries. 

(e)    The Issuer indirectly owns all of the outstanding Capital Stock of each of the
Cedant, PPM Holdings, Inc., Jackson National Asset Management, LLC, Jackson National Life Insurance Company of New York and Jackson Finance LLC, and there are no options, calls, warrants or convertible or exchangeable securities, or conversion,
preemptive, subscription or other rights, or agreements, arrangements or commitments, in any such case, obligating or which may obligate the Issuer, the Group Companies or any of their Affiliates to issue, sell, purchase, return or redeem (or
establish a sinking fund with respect to redemption) any of the Capital Stock of any of the Cedant, PPM Holdings, Inc., Jackson National Asset Management, LLC, Jackson National Life Insurance Company of New York or Jackson Finance LLC, or securities
convertible into or exchangeable for such Capital Stock, and there are no shares of Capital Stock of any of the Cedant, PPM Holdings, Inc., Jackson National Asset Management, LLC, Jackson National Life Insurance Company of New York or Jackson
Finance LLC reserved for issuance for any purpose. Jackson Finance LLC holds valid legal title to the 4.498% surplus note due November 6, 2059 issued by Brooke Life Insurance Company in an aggregate principal amount of $2,000,000,000. 

Section 4.06    Financial Statements; Absence of Undisclosed Liabilities. 

(a)    The Issuer has provided to the Buyer true, complete and correct copies of
(i) the audited consolidated financial statements (consisting of a balance sheet, income statement and statement of cash flows), including the related footnotes, as of and for the year ended December 31, 2018 (the “Audited
Financial Statements”) of the Group Companies and (ii) the unaudited financial statements (consisting of a balance sheet, income statement and statement of cash flows), including the related footnotes, as of and for the calendar
quarter ended March 31, 2020 of the Group Companies (the “Interim Financial Statements” and, together with the Audited Financial Statements, the “GAAP Financial Statements”). The GAAP Financial Statements
(A) have been prepared in all material respects in accordance with GAAP applied consistently throughout the periods involved (except as described in the notes thereto) and (B) present fairly, in all material respects, the
financial position and results of operations of the Group Companies as of their respective dates and for the respective periods covered thereby in 

  
 15 

  

 
accordance with GAAP; provided that the Interim Financial Statements (1) are subject to normal year-end adjustments that are not
material, individually or in the aggregate, and (2) do not include footnotes that, if presented, would differ materially from those footnotes presented in the Audited Financial Statements. 

(b)    The Issuer has provided to the Buyer true, complete and correct copies of
(i) the annual statement and audited SAP financial statements, including the related footnotes, as of and for the years ended December 31, 2018 and December 31, 2019 (the “Annual SAP Financial Statements”) and
(ii) the quarterly statement as of and for the calendar quarter ended March 31, 2020 (together with the Annual SAP Financial Statements, the “SAP Financial Statements”) of each of the Insurance Companies that are
organized in the United States. The SAP Financial Statements (A) have been prepared in all material respects in accordance with applicable SAP applied consistently throughout the periods involved (except as described in the notes
thereto) and (B) present fairly, in all material respects, the financial position and results of operations of the respective Insurance Companies as of their respective dates and for the respective periods covered thereby in accordance
with applicable SAP. No material deficiency has been asserted in writing and, to the Knowledge of the Issuer, no material deficiency has been orally asserted, by any Governmental Authority with respect to any of the SAP Financial Statements. 

(c)    Except (i) as set forth in Section 4.06(c) of
the Disclosure Schedule or to the extent reflected or reserved for in the Financial Statements or disclosed in the notes thereto, (ii) for Liabilities and obligations incurred in the ordinary course of business since December 31,
2019, or (iii) as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, there are no Liabilities or obligations of the Group Companies of any nature (whether accrued, absolute, contingent
or otherwise) of a type that would be required to be disclosed, reflected or reserved for on a balance sheet prepared in accordance with GAAP or SAP, as applicable. 

(d)    Since January 1, 2018, none of the Insurance Companies has sought approval for a permitted accounting practice
that was not granted by the applicable insurance regulator. 
 (e)    Each Group Company maintains, in all material
respects, accurate books and records reflecting its assets and liabilities and proper and adequate systems of internal accounting controls designed to provide assurance that: (i) transactions are executed with management’s general
or specific authorization; (ii) transactions are recorded as necessary to permit preparation of its financial statements in conformity in all material respects with SAP or GAAP, as applicable, and to maintain accountability for its
assets; and (iii) access to its assets is permitted only in accordance with management’s general or specific authorization, except where the failure to maintain such books and records or accounting controls, individually or in the
aggregate, would not reasonably be expected to be material to the Group Companies, taken as a whole. 
 (f)    Except as
set forth in Section 4.06(f) of the Disclosure Schedule, to the Knowledge of the Issuer, none of the Issuer or its Subsidiaries or any of their respective Representatives has received any
non-frivolous written complaint, allegation, assertion or claim 

  
 16 

  

 
regarding the accounting, reserving or auditing practices, procedures, methodologies or methods of any such Subsidiary or the Issuer or their respective internal accounting controls, including
any complaint, allegation, assertion or claim that any such Subsidiary or the Issuer has engaged in questionable accounting, reserving or auditing practices. 

Section 4.07    Absence of Certain Changes. Except as (a) contemplated by this Agreement or (b) as set forth in
Section 4.07 of the Disclosure Schedule, from December 31, 2019 to the date of this Agreement: (i) the Group Companies have conducted the Business in the ordinary course consistent with past practice,
(ii) there has not occurred any event or events that, individually or in the aggregate, have had, or would reasonably be expected to have, a Material Adverse Effect and (iii) none of the Group Companies or any of their
Affiliates have taken any action or failed to take any action that, if taken or failed to be taken after the date hereof without the consent of the Buyer, would constitute a breach of Section 6.01. 

Section 4.08    Absence of Litigation. There are no Actions pending or, to the Knowledge of the Issuer,
threatened against the Issuer or any of its Affiliates that (a) question the validity of, or seek injunctive relief with respect to, this Agreement or the right of the Issuer to enter into this Agreement or (b) would
reasonably be expected to result in damages that have had, or would reasonably be expected to have, a Material Adverse Effect. 

Section 4.09    Compliance with Laws. 

(a)    Since January 1, 2018, none of the Group Companies has been in violation of any Laws or Governmental Orders or
material agreement with any Governmental Authorities, in each case, applicable to them or their assets, properties or businesses, except for violations that, individually or in the aggregate, would not reasonably be expected to result in material
liability to the Group Companies, taken as a whole. 
 (b)    None of the Group Companies are a party to, or bound by,
any material Governmental Order or material agreement with any Governmental Authorities, in each case, applicable to them or their assets, properties or businesses. 

(c)    To the extent required under applicable Law, all policy forms and rates in use by an Insurance Company with respect
to the Insurance Contracts are on forms approved by the applicable Governmental Authorities or which have been filed and not objected to by such Governmental Authorities within the period provided for objection, in each case, except as would not
reasonably be expected to result in a material violation of applicable Law. 
 (d)    Each Group Company has in place
risk management, business continuity and disaster recovery policies and procedures that comply with applicable Law and are sufficient in scope and operation to protect against risks of the types reasonably expected to be incurred by Persons
similarly situated, except where the absence of such policies, individually or in the aggregate, would not reasonably be expected to result in material liability to the Group Companies, taken as a whole. 

  
 17 

  

 Section 4.10    Taxes. Except
as set forth in Section 4.10 of the Disclosure Schedule: 
 (a)    All
(i) material Tax Returns required to be filed by or with respect to the Group Companies have been duly and timely filed with the appropriate Tax Authority (after giving effect to any extensions of time properly obtained in which to make
such filings), (ii) such Tax Returns are correct and complete in all material respects and (iii) amounts shown on such Tax Returns as due and all other material Taxes payable by or with respect to any of the Group Companies
have been fully and timely paid. 
 (b)    The Group Companies have complied in all material respects with applicable
Law relating to withholding of Taxes and have duly and timely withheld and paid over to the appropriate Tax Authority all material amounts required to be so withheld and paid over. 

(c)    No written waiver of any statute of limitations relating to income Taxes or other material Taxes for which the
Group Companies are liable and that remains in effect has been granted. 
 (d)    To the Knowledge of the Issuer, there
is no action, investigation, claim, assessment, audit or examination pending, proposed or threatened in writing with respect to material Taxes of the Group Companies. 

(e)    During the past three (3) years, no Group Company has been a “distributing corporation” or a
“controlled corporation” within the meaning of section 355 of the Code. 
 (f)    No Group Company has
participated in a “listed transaction” within the meaning of Treasury Regulations section 1.6011-4(c) within the last five years. 

(g)    During the past six (6) years, no claim has been made in writing by a Tax Authority in a jurisdiction where
any Group Company has never paid a particular type of Tax or filed a particular type of Tax Return asserting that such Group Company is required to pay such Tax or file such Tax Return in such jurisdiction, in each case, that has not been resolved.

 (h)    This Section 4.10 and Section 4.11 contain the sole and
exclusive representations and warranties related to Tax matters. Nothing in this Section 4.10 or otherwise in this Agreement shall be construed as a representation or warranty with respect to (i) the amount or
availability of any net operating loss, capital loss, Tax credit, Tax basis or other Tax asset or attribute of the Issuer or (ii) any Tax period or portion thereof beginning after the Closing Date. 

Section 4.11    Tax Treatment of Insurance Contracts. 

(a)    The Tax treatment of each Insurance Contract is not, and since the time of issuance or subsequent modification has
not been, less favorable to the purchaser, policyholder or intended beneficiaries thereof, than the Tax treatment under the Code either that was purported to apply in written materials provided by the issuer of such Insurance Contract, in each

  
 18 

  

 
case at the time of its issuance (or any subsequent modification of such Insurance Contract) or for which such Insurance Contract was designed to qualify at the time of issuance (or subsequent
modification), in each case except where the failure to have such Tax treatment, individually or in the aggregate, is not, and would not reasonably be expected to be, material to the issuer of any such Insurance Contract. 

(b)    None of the Insurance Companies or any of their respective Affiliates has entered into any agreement or is involved
in any discussions or negotiations with any Tax Authority regarding the failure of any Insurance Contracts to meet the requirements of the Product Tax Rules. None of the Insurance Companies or any of their respective Affiliates is a party to, or has
received written notice of, any federal, state, local or foreign audits or other administrative or judicial actions with regard to the Tax treatment of any Insurance Contracts or of any claims by the purchasers, holders or intended beneficiaries of
the Insurance Contracts regarding the Tax treatment of (i) the Insurance Contracts or (ii) any plan or arrangement in connection with which such Insurance Contracts were purchased or have been administered. 

Section 4.12    Brokers. The Issuer (or one of its Affiliates) is solely responsible for the payment of the
fees and expenses of any broker, investment banker, financial adviser or other Person acting in a similar capacity in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Issuer or any
of its Affiliates. 
 Section 4.13    Governmental Licenses and Permits. 

(a)    Each Group Company owns, holds or possesses all material Governmental Approvals,
qualifications, registrations, consents, licenses, permits, certificates or authorizations that are necessary for it to conduct its business and to own or use its assets and properties, as such business, assets and properties are conducted, owned
and used on the date hereof (collectively, the “Permits”) except where the failure to hold such Permit, individually or in the aggregate, would not reasonably be expected to result in material liability to the Group
Companies, taken as a whole. 
 (b)    Except as set forth in Section 4.13(b) of the
Disclosure Schedule or as would not reasonably be expected to result in material liability to the Group Companies, taken as a whole, (i) all of the Permits are valid and in full force and effect, (ii) none of the Group
Companies is in default or violation, in any material respect, of any of the Permits and (iii) none of the Group Companies are the subject of any pending or, to the Knowledge of the Issuer, threatened Action seeking the revocation,
suspension, limitation, termination, modification, cancellation, impairment or non-renewal of any of the Permits. 

Section 4.14    Material Contracts. 

(a)    Section 4.14(a) of the Disclosure Schedule contains a complete and correct list of each
Material Contract in force or under which any Group Company has material continuing obligations as of the date hereof. A “Material Contract” is any contract (other than Insurance Contracts and any contracts that relate to the
acquisition, disposition or custody of investment assets in the ordinary course of business consistent with past practice) to which any Group Company is a party or is otherwise bound or obligated, in each case, that: 

(i)    contains covenants limiting the ability of any Group Company in any material respect to engage in
any line of business or to compete with any Person that would purport to apply to the Buyer or its Affiliates following the Closing; 

  
 19 

  

 (ii)    contains any material restriction on the ability
of any Group Company or any of their Affiliates to solicit specified customers or prospective customers for the purchase, renewal, lapse, surrender or annuitization of Insurance Contracts or to alter or change the terms, features, benefits,
elections or options under the Insurance Contracts, in each case that would purport to apply to the Buyer or its Affiliates following the Closing; 

(iii)    relates to the acquisition or disposition of any Person or business or a material portion of the
assets of any Person or business (whether by merger, sale of stock, sale of assets or otherwise) under which any Group Company has material continuing rights, obligations or liabilities; 

(iv)    is between any Group Company, on the one hand, and any Affiliate of the Issuer (other than the
Group Companies), on the other hand; or 
 (v)    obligates any Group Company to enter into any of the
foregoing. 
 (b)    The Issuer has made available to the Buyer a complete and correct copy of each Material Contract as
of the date of this Agreement. None of the Group Companies or, to the Knowledge of the Issuer, any other party to a Material Contract, is in material default or material breach or has failed to perform any material obligation under a Material
Contract, and, to the Knowledge of the Issuer, there does not exist any event, condition or omission that would constitute such a material breach or material default (whether by lapse of time or notice or both). None of the Group Companies or, to
the Knowledge of the Issuer, any other party to a material outbound reinsurance agreement to which a Group Company is party, is in material default or material breach or has failed to perform any material obligation under such a material outbound
reinsurance agreement. 
 Section 4.15    NO OTHER REPRESENTATIONS OR WARRANTIES. NOTWITHSTANDING ANYTHING
TO THE CONTRARY CONTAINED IN THIS AGREEMENT, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS ARTICLE IV (AS MODIFIED BY THE DISCLOSURE SCHEDULE), NEITHER THE ISSUER NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR
IMPLIED REPRESENTATION OR WARRANTY WITH RESPECT TO THE ISSUER, THE BUSINESS, THE PURCHASED SHARES, OR THE ASSETS AND PROPERTIES OF THE GROUP COMPANIES, AND THE ISSUER DISCLAIMS ANY OTHER REPRESENTATIONS, WARRANTIES, FORECASTS, PROJECTIONS,
STATEMENTS OR INFORMATION, WHETHER MADE BY THE ISSUER OR ANY OF ITS AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES, PRODUCERS OR REPRESENTATIVES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE
IV (AS MODIFIED BY THE DISCLOSURE SCHEDULE), NO REPRESENTATION OR WARRANTY HAS BEEN OR IS BEING MADE WITH RESPECT TO ANY PROJECTIONS, FORECASTS, BUSINESS PLANS, ESTIMATES OR BUDGETS DELIVERED OR MADE AVAILABLE TO THE BUYER OR ANY OTHER
PERSON. 

  
 20 

  

 ARTICLE V 

REPRESENTATIONS AND WARRANTIES REGARDING THE BUYER 

The Buyer hereby represents and warrants to the Issuer as follows as of the date hereof and as of the Closing Date (except for such
representations and warranties which address matters only as of a specific date, which representations and warranties shall be true and correct as of such specific date): 

Section 5.01    Incorporation and Authority of the Buyer. 

(a)    The Buyer is a corporation duly incorporated, validly existing and in good standing under the Laws of the
jurisdiction of its incorporation. 
 (b)    The Buyer has all requisite corporate or other power to enter into,
consummate the transactions contemplated by, and carry out its obligations under, this Agreement and the other Transaction Agreements to which it is or will be a party. The execution and delivery by the Buyer of this Agreement and the other
Transaction Agreements to which it is or will be a party, the consummation by the Buyer of the transactions contemplated by and the performance by the Buyer of its obligations under this Agreement and the other Transaction Agreements to which it is
or will be a party have been duly authorized by all requisite corporate or other action on the part of the Buyer. This Agreement has been duly executed and delivered by the Buyer, and this Agreement and the other Transaction Agreements to which it
is or will be a party constitute (assuming due authorization, execution and delivery by the Issuer and each other party thereto) the legal, valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms,
subject to the effect of any applicable bankruptcy, reorganization, insolvency, moratorium, rehabilitation, liquidation, fraudulent conveyance or similar Laws relating to or affecting creditors’ rights generally and subject, as to
enforceability, to the effect of general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). 

Section 5.02    No Conflict. Provided that all consents, approvals, authorizations and other actions described
in Schedule 5.03 have been obtained or taken, except as otherwise provided in this Article V, the execution, delivery and performance by the Buyer of, and the consummation by the Buyer of the transactions
contemplated by, this Agreement and the other Transaction Agreements to which it is or will be a party do not (a) violate or conflict with the organizational documents of the Buyer, (b) violate or conflict with any Law or
other Governmental Order applicable to the Buyer or by which it or its properties or assets is bound or subject or (c) result in any breach of, or constitute a default (or event which, with the giving of notice or lapse of time, or both,
would become a default) under, or give to any Person any rights of termination, acceleration, impairment or cancellation of, or result in the creation of any Lien (other than Permitted Liens) on any of the assets, rights or properties of the Buyer
pursuant to, or result in any acceleration of remedies, penalty or material increase or decrease in an amount payable or an obligation or benefit under, any material note, bond, mortgage, indenture or contract to which the Buyer or any of its
Subsidiaries is a party or by which any of such assets or 

  
 21 

  

 
properties is bound or subject, except, in the case of clauses (b) or (c), any such conflicts, violations, breaches, defaults, rights or Liens that, individually or in the aggregate, do
not have, and would not reasonably be expected to have, a Buyer Material Adverse Effect. 

Section 5.03    Consents and Approvals. Except as set forth in Schedule 5.03, the execution and
delivery by the Buyer of this Agreement and the other Transaction Agreements to which it is or will be a party do not and will not, and the performance by the Buyer of, and the consummation by the Buyer of the transactions contemplated by, this
Agreement and the other Transaction Agreements to which it is or will be a party do not and will not require any Governmental Approval to be obtained or made by the Buyer or any of its Affiliates prior to the Closing, except for such Governmental
Approvals, the failure of which to be obtained or made has not had, and would not reasonably be expected to have, a Buyer Material Adverse Effect. 

Section 5.04    Absence of Litigation. There are no Actions pending or, to the Knowledge of the Buyer,
threatened in writing, against the Buyer that (a) question the validity of, or seek injunctive relief with respect to, this Agreement or the right of the Buyer to enter into this Agreement or (b) would reasonably be expected
to result in damages that have had, or would reasonably be expected to have, a Buyer Material Adverse Effect. 

Section 5.05    Compliance with Law. 

(a)    Since January 1, 2018, neither the Buyer nor any of its Affiliates has been in violation of any applicable Law
or Governmental Order or material agreement with any Governmental Authorities, in each case, applicable to them or their assets, properties or businesses, except for violations that, individually or in the aggregate, would not reasonably be expected
to result in material impairment or delay of the ability of the Buyer to perform its material obligations under this Agreement, including consummation of the transactions contemplated hereby. 

(b)    Neither the Buyer nor any of its Affiliates is a party to, or bound by, or has Knowledge of, any Governmental Order
or any investigation, examination or inquiry by any Governmental Authority, or any agreement with or commitment to any Governmental Authority, in each case, applicable to them or any their officers, directors, employees, shareholders, partners,
assets, properties or businesses, that would reasonably be expected to result in material impairment or delay of the ability of the Buyer to perform its material obligations under this Agreement, including consummation of the transactions
contemplated hereby. 
 Section 5.06    Securities Matters. The Purchased
Shares are being acquired by the Buyer for its own account and without a view to the public distribution or sale of the Purchased Shares or any interest in them. The Buyer acknowledges that the Purchased Shares have not been registered under the
Securities Act or under any state securities laws. The Buyer (a) acknowledges that it is acquiring the Purchased Shares pursuant to an exemption from registration under the Securities Act solely for investment with no present intention
to distribute any of the Purchased Shares to any Person in violation of applicable securities laws, (b) will not sell or otherwise dispose of any of the Purchased Shares, except in compliance with the registration requirements or
exemption provisions of the Securities Act and any other applicable securities laws and the Transaction Agreements, (c) has such knowledge and experience in 

  
 22 

  

 
financial and business matters and in investments of this type that it is capable of evaluating the merits and risks of its investment in the Purchased Shares and of making an informed investment
decision, (d) is an “accredited investor” (as that term is defined by Rule 501 of the Securities Act), (e) is a “qualified institutional buyer” (as that term is defined in Rule 144A of the Securities Act),
and (f) has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risks of its investment in the Purchased Shares, and the Buyer is capable of bearing the economic risks of
such investment, including a complete loss of its investment in the Purchased Shares. The Buyer understands that it may not sell, transfer, assign, pledge or otherwise dispose of any of the Purchased Shares other than pursuant to a registered
offering in compliance with, or in a transaction exempt from, the registration requirements of the Securities Act and applicable state and foreign securities Laws. 

Section 5.07    Financial Ability. The Buyer has, and will have at the Closing, sufficient immediately
available funds to pay, in cash, the Purchase Price and all other amounts payable pursuant to the Transaction Agreements. Neither the Buyer nor any of its Affiliates has incurred any Liabilities or obligations, or is contemplating or aware of any
Liabilities or obligations, in either case, that would impair or adversely affect such resources and capabilities. The obligations of the Buyer to effect the transactions contemplated by this Agreement and the other Transaction Agreements are not
conditioned upon the availability to the Buyer or any of its Affiliates of any debt, equity or other financing in any amount whatsoever. 

Section 5.08    Investigation. The Buyer (a) has made its own inquiry and investigation into, and,
based thereon, has formed an independent judgment concerning, the Purchased Shares, the Group Companies and the Business and (b) has been furnished with or given access to such information about the Purchased Shares, the Group Companies
and the Business as it has requested. The only representations and warranties made by the Issuer or any of its Affiliates are the representations and warranties expressly made in this Agreement and the other Transaction Agreements to which the
Issuer or any of its Affiliates is a party and neither the Issuer nor any of its Affiliates makes any other express or implied representation or warranty with respect to (i) the Purchased Shares, the Group Companies and the Business, or
(ii) any information provided by the Issuer or any of its Affiliates or Representatives in any management meetings, the Electronic Data Room, or otherwise, including as to the probable success or profitability of the ownership of the
Purchased Shares after the Closing. 
 Section 5.09    Brokers. The Buyer is solely responsible for the
payment of the fees and expenses of any broker, investment banker, financial adviser or other Person acting in a similar capacity in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the
Buyer or any Affiliate of the Buyer. 
 Section 5.10    No Inducement or Reliance; Independent
Assessment. 
 (a)    The Buyer acknowledges and agrees that none of the Issuer, the Group Companies or their
respective Affiliates or Representatives has made any representations or warranties other than those set forth in Article IV. Except for the representations and warranties of the Issuer expressly set forth herein or in any
Transaction Agreement, the Buyer has not relied upon any representations or warranties or other information made or supplied by or on behalf of the Issuer or by any Affiliate of the Issuer. 

  
 23 

  

 (b)    Without limiting the foregoing, except for the representations
and warranties set forth in Article IV or in the other Transaction Agreements to which the Issuer or any of its Affiliates is a party, none of the Issuer or its Affiliates or Representatives makes, will make or has made any
representation or warranty, express or implied, as to: 
 (i)    the prospects of the Purchased Shares or
their profitability for the Buyer, or with respect to any forecasts, projections or business plans made available to the Buyer or any other Person (including the Buyer’s Affiliates or Representatives) in connection with the Buyer’s review
of the Purchased Shares and the Business; or 
 (ii)    any estimates, assumptions, projections and
predictions contained or referred to in the materials that have been provided or made available to the Buyer by or on behalf of the Issuer, including any communication by or on behalf of Milliman, materials in the Electronic Data Room and all
management presentations and information established or provided in connection with the transactions contemplated by this Agreement. 

ARTICLE VI 
 ACTIONS
PRIOR TO THE CLOSING DATE 

Section 6.01    Conduct of Business Prior to the
Closing. Except (i) as required by applicable Law, (ii) as expressly required or expressly permitted by the terms of this Agreement or (iii) as set forth in Section 6.01 of the
Disclosure Schedule, from the date of this Agreement through the Closing Date, unless the Buyer otherwise consents in writing in advance (which consent shall not be unreasonably withheld, delayed or conditioned), the Issuer shall cause the Group
Companies to conduct the Business in the ordinary course, consistent with past practice (except in response to or related to any Contagion Event or any change in applicable Law or policy as a result of or related to any Contagion Event), and shall
refrain from taking any of the following actions: 
 (a)    (i) transfer, issue, sell, redeem, cancel,
purchase or otherwise dispose of or encumber any Capital Stock or other securities of the Issuer, (ii) pledge, grant or enter into any options, warrants, calls, agreements or other rights to purchase or otherwise acquire Capital Stock or
other securities of the Issuer, (iii) accelerate the vesting of any options, warrant, calls agreements or other rights to purchase or otherwise acquire Capital Stock or other securities of the Issuer or (iv) amend any terms
of any equity securities or any agreements relating to any equity securities of the Issuer; 
 (b)    effect any
recapitalization, reclassification, stock split or combination or similar change in the capitalization of the Issuer, or reincorporate or domesticate the Issuer; 

(c)    any action that would require the prior consent of the Buyer under Section 2.4 of the Stockholders Agreement,
assuming the Stockholders Agreement were in effect and the Shares were issued and outstanding at the time of such action; 

(d)    declare, set aside or pay any dividends on, or make any distributions (whether in cash, stock or property) in
respect of the Common Stock; or 

  
 24 

  

 (e)    enter into any legally binding commitment with respect to any of
the foregoing. 
 Section 6.02    Access to Information. 

(a)    In furtherance of the consummation of the transactions contemplated by this Agreement, from the date of this
Agreement until the Closing Date, the Issuer shall, and shall cause the other Group Companies to, provide the Buyer, its Affiliates and their authorized Representatives with, upon reasonable advance written notice and during regular business hours,
reasonable access to all books, records, personnel, officers and other facilities and properties of the Issuer and the other Group Companies; provided that any such access shall be conducted at the Buyer’s expense, in
accordance with applicable Law (including any applicable Law relating to antitrust, competition, employment or privacy issues), under the supervision of the Issuer’s or its Affiliates’ personnel and in such a manner as to maintain
confidentiality and not to unreasonably interfere with the normal operations of the Issuer and its Affiliates. 

(b)    Notwithstanding anything to the contrary contained in this Agreement or any other agreement between the Buyer and
the Issuer or any of its Affiliates executed on or prior to the date hereof (other than as set forth in the Reinsurance Agreement), the Issuer shall have no obligation to, or to cause the other Group Companies to, make available to the Buyer, its
Affiliates or their Representatives, or to provide the Buyer, its Affiliates or their Representatives with access to or copies of (i) any personnel file, medical file or related records of any employee of any of the Group Companies,
(ii) any Tax Return filed by the Issuer or any of its Affiliates or predecessors, or any related material or (iii) any other information if the Issuer determines, in its reasonable judgment, that making such other information
available would (A) jeopardize any attorney-client privilege, the work product immunity or any other legal privilege or similar doctrine or (B) contravene any applicable Law, Governmental Order or fiduciary duty, it being
understood that the Issuer shall and shall cause the other Group Companies to (x) cooperate with any requests for, and use their reasonable best efforts to obtain any, waivers and (y) use their reasonable best efforts to make
other arrangements (including redacting information or entering into joint defense agreements), in each case, that would enable any otherwise required disclosure to the Buyer, its Affiliates or their Representatives to occur without so jeopardizing
any such privilege or immunity or contravening such applicable Law, Governmental Order or fiduciary duty. 

Section 6.03    Reasonable Best Efforts; Consents. 

(a)    Upon the terms and subject to the conditions set forth in this Agreement, each of the Issuer and the Buyer agrees to
use, and shall cause their respective Affiliates to use, reasonable best efforts to take, or cause to be taken, all reasonable actions and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all reasonable things
necessary, proper or advisable to fulfill all conditions applicable to such party’s obligations pursuant to this Agreement to consummate and make effective as soon as reasonably practicable the Closing and the other transactions contemplated
hereby, including using reasonable best efforts to (i) obtain all necessary, proper or advisable Governmental Approvals and making all necessary, proper or advisable registrations, filings and notices (including under the HSR Act) and
(ii) execute and deliver any additional agreements, documents or instruments necessary, proper or advisable to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement. 

  
 25 

  

 (b)    Without limiting the foregoing, each of the Buyer and the Issuer
shall use, and shall cause their respective Affiliates to use, reasonable best efforts to: (i) obtain all Governmental Approvals necessary, proper or advisable to consummate the transactions contemplated by this Agreement and secure the
expiration or termination of any applicable waiting period under the HSR Act, (ii) resolve any objections that may be asserted by any Governmental Authority with respect to the Closing or any other transaction contemplated hereby and
(iii) prevent the entry of, and have vacated, lifted, reversed or overturned, any Governmental Order that would prevent, prohibit, restrict or delay the consummation of the Closing or any other transaction contemplated hereby;
provided, however, that the efforts required by this Section 6.03 shall not require, or be construed to require, the Buyer, the Issuer or any of their respective Affiliates to agree to sell, hold separate,
divest, discontinue or limit, before or after the Closing Date, any assets, businesses or interest in any of their respective assets or businesses; provided, further, that the inclusion of a reference to any action in this sentence
shall not imply that reasonable best efforts would require a party to take such action. 
 (c)    The Buyer shall not,
and shall cause its Affiliates not to, directly or indirectly (whether by merger, consolidation or otherwise), acquire, purchase, lease or license (or agree to acquire, purchase, lease or license) any business, corporation, partnership, association
or other business organization or division or part thereof, or any securities or collection of assets for forty-five (45) days following the date hereof, if doing so would reasonably be expected to impose any material delay in securing the
expiration or termination of any applicable waiting period under the HSR Act. 
 (d)    In furtherance and without
limiting the foregoing, (i) each of the Issuer (or its applicable Affiliate) and the Buyer shall file a notification and report form pursuant to the HSR Act with the Federal Trade Commission and the Antitrust Division of the United
States Department of Justice with respect to the Closing and the other transactions contemplated hereby and requesting early termination of the waiting period under the HSR Act, within ten (10) Business Days of the date hereof and
(ii) the parties shall make any other registrations, filings and notices of, with or to Governmental Authorities necessary, proper or advisable to consummate the transactions contemplated by this Agreement within fifteen
(15) Business Days of the date hereof. All filing fees payable in connection with the foregoing shall be borne by the Buyer. Each of the Buyer and the Issuer agrees promptly to provide, or cause to be provided, all agreements, documents,
instruments, affidavits, statements or information that may be required or reasonably requested by any Governmental Authority relating to it or any of its Affiliates (including any of their respective directors, officers, employees or direct or
indirect investors, partners, members, shareholders or “Ultimate Parent Entities” (as that term is defined in the HSR Act)), or its or their structure, ownership, businesses, operations, regulatory and legal compliance, assets,
liabilities, financing, financial condition or results of operations, or any of its or their directors, officers, employees, or direct or indirect partners, members or shareholders. 

(e)    Each of the Issuer, on the one hand, and the Buyer, on the other hand, agrees that it shall consult with one
another with respect to the obtaining of all Governmental Approvals necessary, proper or advisable to consummate the transactions contemplated by this 

  
 26 

  

 
Agreement and each of them shall keep the others apprised on a prompt basis of the status of matters relating to such Governmental Approvals. The Issuer and the Buyer shall have the right to
review in advance, subject to redaction of personally identifiable information or confidential, competitive information, and, to the extent practicable, and subject to any restrictions under applicable Law each shall consult the other on, any filing
made with, or written materials submitted to, any Governmental Authority or any third party in connection with the transactions contemplated by this Agreement, and each party agrees to in good faith consider and reasonably accept comments of the
other parties thereon. The Issuer and the Buyer shall promptly furnish to each other copies of all such filings and written materials after their filing or submission, in each case subject to applicable Law and subject to redaction as described
above. 
 (f)    The Issuer and the Buyer shall promptly (and in no event later than twenty-four (24) hours after
receipt) advise each other upon receiving any communication from any Governmental Authority whose Governmental Approval is required for consummation of the transactions contemplated by this Agreement to the extent such communication reasonably
relates to such required Governmental Approval, including promptly furnishing each other copies of any written or electronic communications, and shall promptly advise each other when any such communication causes such party to believe that there is
a reasonable likelihood that any such consent or Governmental Approval will not be obtained or that the receipt of any such Governmental Approval will be materially delayed or conditioned. 

(g)    Neither the Issuer nor the Buyer shall, and they shall cause their respective Affiliates not to, permit any of
their respective directors, officers, employees, partners, members, shareholders or any other Representatives to participate in any live or telephonic meeting (other than non-substantive scheduling or
administrative calls) with any Governmental Authority required for the consummation of the transactions contemplated by this Agreement unless it consults with the other in advance and, to the extent permitted by applicable Law and by such
Governmental Authority, gives the other party the opportunity to attend and participate in such meeting. 

(h)    Notwithstanding anything in this Agreement to the contrary, in no event shall any Group Company or any of their
Affiliates or the Buyer or any of its Affiliates be required to agree to take or enter into any action which would be required to be taken in the event that the Closing does not occur. 

(i)    Prior to the Closing, except as otherwise agreed by the parties, each party shall cooperate with the other and use
reasonable best efforts to make or obtain the Third-Party Consents set forth in Schedule 6.03(i); provided that neither party shall be required to compromise any
right, asset or benefit or expend any amount or incur any Liabilities, make any accommodations, commence or participate in any Action or provide any other consideration in order to obtain any such Third-Party
Consent. 
 (j)    The Buyer’s or the Issuer’s breach of any of their respective obligations in this
Section 6.03 that contributes in any material way to a failure of the Closing to occur shall constitute a willful breach of this Agreement. 

  
 27 

  

 Section 6.04    Closing Deliverables. Each of the Issuer and
the Buyer shall, and each shall cause its applicable Affiliates to, enter into each of the Transaction Agreements at the Closing, in each case in substantially the form attached as an Exhibit to this Agreement. 

Section 6.05    Restructuring. In the event that the waiting period under the HSR Act has expired or been
terminated, but the parties are awaiting any approval or non-disapproval under applicable insurance Laws, then the Issuer may, within ten (10) Business Days following such expiration or termination, elect
to cause the Closing to occur with respect only to Common Shares representing less than ten percent (10%) of both voting and economic rights in the Issuer. The parties will cooperate to make all changes necessary to the Purchase Price and the
Transaction Agreements in order to reflect a Closing with respect to such smaller number of Common Shares (the “Initial Closing”) as promptly as reasonably practicable. Within five (5) Business Days following such Initial
Closing, the Issuer will have the right to elect to proceed with a second closing on the remainder of the Purchased Shares for the remainder of the Purchase Price, as promptly as reasonably practicable, after receipt of any remaining insurance
regulatory approvals or non-disapprovals and subject to the other terms and conditions of this Agreement. 

ARTICLE VII 

ADDITIONAL AGREEMENTS 

Section 7.01    Confidentiality. 

(a)    The terms of the Confidentiality Agreement between Prudential Services Limited and Apollo Management Holdings, L.P.
dated December 9, 2019 (the “Confidentiality Agreement”) are incorporated into this Agreement by reference and shall continue in full force and effect until the Closing, at which time the confidentiality
obligations under the Confidentiality Agreement shall terminate. If for any reason the transactions contemplated by this Agreement are not consummated, the Confidentiality Agreement shall continue in full force and effect in accordance with its
terms (disregarding, however, any provision contained therein that provides for termination thereof upon the execution of this Agreement). 

(b)    From and after the Closing, the Issuer and its Affiliates shall, and shall cause their respective Representatives
to, maintain in confidence any written, oral or other information relating to the negotiation of this Agreement, or any proprietary or confidential information related to or obtained from the Buyer or any of its Affiliates or Representatives prior
to the Closing Date. 
 (c)    From and after the Closing, the Buyer and its Affiliates shall, and shall cause their
respective Representatives to, maintain in confidence any written, oral or other information relating to the negotiation of this Agreement or any proprietary or confidential information related to or obtained from the Issuer or any of its Affiliates
prior to the Closing Date. 
 (d)    The requirements of Section 7.01(b) and
Section 7.01(c) shall not apply to the extent that (i) any such information is or becomes generally available to the public other than (A) in the case of the Buyer, as a result of disclosure by the
Issuer, any of its Affiliates or any of 

  
 28 

  

 
their respective Representatives and (B) in the case of the Issuer, as a result of disclosure by the Buyer or any of its Affiliates or Representatives, (ii) any such
information is required or requested by applicable Law, Governmental Order or a Governmental Authority to be disclosed, (iii) any such information is reasonably necessary to be disclosed in connection with any Action (other than any
Action arising out of or in relation to this Agreement), (iv) any such information was or becomes available to such party on a non-confidential basis and from a source (other than a party to this
Agreement or any Affiliate or Representative of such party) that is not bound by a confidentiality agreement with respect to such information or (v) any such information that is required or permitted to be disclosed under the terms of
the Stockholders Agreement, the Registration Rights Agreement or the Reinsurance Agreement. Each of the parties hereto shall instruct its Affiliates and its Representatives having access to such information of such confidentiality obligations. 

Section 7.02    Further Action. 

(a)    Each of the Issuer and the Buyer (i) shall execute and deliver, or shall cause to be executed and
delivered, such documents and other papers and shall take, or shall cause to be taken, such further actions as may be reasonably required to carry out the provisions of this Agreement and give effect to the transactions contemplated by this
Agreement, (ii) subject to Section 6.03(b), shall refrain from taking any actions that could reasonably be expected to impair, delay or impede the Closing, (iii) without limiting the foregoing, but
subject to Section 6.03, shall use their respective reasonable best efforts to cause all the conditions to the obligations of the other parties to consummate the transactions contemplated by this Agreement to be met as soon
as reasonably practicable and (iv) shall cooperate in good faith to facilitate an orderly Closing. 

(b)    Each of the Issuer and the Buyer shall keep the other reasonably apprised of the status of the matters relating to
the completion of the transactions contemplated hereby, including with respect to the satisfaction of the conditions set forth in Article VIII. From time to time following the Closing, the Issuer and the Buyer shall, and
shall cause their respective Affiliates to, execute, acknowledge and deliver all reasonable further conveyances, notices, assumptions, releases and acquittances and such instruments, and shall take such reasonable actions as may be necessary or
appropriate to make effective the transactions contemplated hereby as may be reasonably requested by the other parties. 

Section 7.03    Standstill. For a period beginning on the date of this Agreement and ending at 5:00 p.m., New
York City time, on the day that the Capital Stock of the Issuer owned by the Buyer and its Affiliates no longer exceeds ten percent (10%) or greater of the total Capital Stock of the Issuer outstanding, the Buyer shall not, and shall cause Athene
Holding Ltd. and Athene Holding Ltd.’s Controlled Affiliates not to, (a) acquire, agree to acquire, propose or offer or take any step that would be reasonably likely to result in an obligation to make an offer to acquire, by
purchase or otherwise, any interest in Capital Stock of Parent, (b) otherwise act, alone or in concert with others, to seek to control or influence the management or policies of Parent, (c) take any action that would
reasonably be expected to require Parent to make a public announcement regarding any of the events described in clauses (a) or (b), (d) advise or knowingly assist or knowingly encourage or enter into any discussions, negotiations,
agreements or arrangements with any other Persons in connection with the foregoing, (e) form, join or in any 

  
 29 

  

 
way participate in a “group” or concert party with respect to any interest in Capital Stock of Parent or any exercise of voting rights attaching to any Capital Stock of Parent or
otherwise in connection with the foregoing or (f) publicly disclose any intention, plan or proposal with respect to any of the foregoing. Notwithstanding the foregoing, the restrictions set forth in this
Section 7.03 shall not apply to ordinary course investment activities by investment funds and managed accounts managed by Affiliates of the Buyer that are passive in nature without the intent or ability to exercise control.

 Section 7.04    Solicitation. For a period beginning on the Closing Date and ending on the earlier of
(i) the first anniversary of the consummation of an IPO and (ii) the second anniversary of the Closing Date, without the prior written consent of the Issuer, neither the Buyer nor any of its Controlled Affiliates, shall,
whether directly or indirectly, solicit for employment the services of (x) any management-level employee of any Group Company or (y) any employee of any Group Company with whom the Buyer or its Controlled Affiliates has
substantial contact in connection with the transactions contemplated by the Reinsurance Agreement; provided that nothing in this Section 7.04 shall prohibit the Buyer or any of its Subsidiaries from
(a) engaging in general solicitations, through third-party recruiters or otherwise, not directed at such Persons or (b) soliciting the services of any such Person whose employment with any Group Company has been terminated
for a period of at least six months prior to the first contact by the Buyer or any of its Controlled Affiliates with such Person. 

ARTICLE VIII 

CONDITIONS TO CLOSING AND RELATED MATTERS 

Section 8.01    Conditions to Obligations of the Issuer and the Buyer. The obligations of the Issuer and the
Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment (or, if permitted by applicable Law, waiver in writing by the party for whose benefit such condition exists), at or prior to the Closing, of each
of the following conditions: 
 (a)    Approvals of Governmental Authorities. The
Governmental Approvals listed in Schedule 8.01(a) shall have been received (or any waiting period shall have expired or shall have been terminated). 

(b)    No Governmental Order. There shall be no Governmental Order of a Governmental Authority of competent
jurisdiction in existence that restrains, enjoins or otherwise prohibits the consummation of the transactions contemplated by this Agreement. 

Section 8.02    Conditions to Obligations of the Issuer. The obligation of the Issuer to consummate the
transactions contemplated by this Agreement shall be subject to the fulfillment (or waiver in writing by the Issuer), at or prior to the Closing, of each of the following conditions: 

(a)    the representations and warranties of the Buyer contained in Section 5.01 shall be true
and correct as of the date hereof and as of the Closing Date as if made on the Closing Date; 

  
 30 

  

 (b)    the other representations and warranties of the Buyer contained
in Article V shall be true and correct (without giving effect to any limitations as to materiality or Buyer Material Adverse Effect set forth therein) as of the date hereof and as of the Closing Date as if made on the
Closing Date (other than any representation or warranty expressly made as of another date, which representation or warranty shall have been true and correct as of such date), except where the failure of such representations and warranties,
individually or in the aggregate, to be true and correct has not had, and would not reasonably be expected to have, a Buyer Material Adverse Effect; 

(c)    the covenants contained in this Agreement to be complied with by the Buyer at or before the Closing shall have been
complied with in all material respects; 
 (d)    the Issuer shall have received a certificate of the Buyer dated as of
the Closing Date, signed by a duly authorized executive officer of the Buyer, certifying the satisfaction of the conditions set forth in clauses (a) through (c) of this Section 8.02; and 

(e)    the Transaction Agreements shall have been duly executed and delivered by the Buyer and its Affiliates, as
applicable, and such agreements shall be in full force and effect with respect to the Buyer and its Affiliates. 

Section 8.03    Conditions to Obligations of the Buyer. The obligations of the Buyer to consummate the
transactions contemplated by this Agreement shall be subject to the fulfillment (or waiver in writing by the Buyer), at or prior to the Closing, of each of the following conditions: 

(a)    the Fundamental Representations shall be true and correct as of the date hereof and as of the Closing Date as if
made on the Closing Date; 
 (b)    the representations and warranties of the Issuer contained in
Article IV (other than the Fundamental Representations) shall be true and correct (without giving effect to any limitations as to materiality or Material Adverse Effect set forth therein) as of the date hereof and as of the
Closing Date as if made on the Closing Date (other than any representation or warranty expressly made as of another date, which representation or warranty shall have been true and correct as of such date), except where the failure of such
representations and warranties, individually or in the aggregate, to be true and correct has not had, and would not reasonably be expected to have, a Material Adverse Effect; 

(c)    the covenants contained in this Agreement to be complied with by the Issuer on or before the Closing shall have
been complied with in all material respects; 
 (d)    the Buyer shall have received a certificate of the Issuer, dated
as of the Closing Date, signed by a duly authorized executive officer of the Issuer, certifying the satisfaction of the conditions set forth in clauses (a) through (c) of this Section 8.03; 

(e)    prior to the filing of the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State,
the Issuer shall have novated the term loan facility dated November 7, 2019 between the Issuer, Parent and Standard Chartered Bank, New York Branch, and all liabilities thereunder to Parent; 

  
 31 

  

 (f)    since the date hereof, there shall not have occurred any fact,
event, circumstance, effect, development, condition, violation or occurrence that, individually or in the aggregate, has had, or would reasonably be expected to have, a Material Adverse Effect; and 

(g)    the Transaction Agreements shall have been duly executed and delivered by the Issuer and its Affiliates, as
applicable, and such agreements shall be in full force and effect with respect to the Issuer and its Affiliates. 
 ARTICLE IX

 SURVIVAL; INDEMNIFICATION; CERTAIN REMEDIES 

Section 9.01    Survival. The representations, warranties, covenants and agreements of the parties hereto
contained in or made pursuant to this Agreement shall survive in full force and effect until the earlier of (x) the consummation of an IPO and (y) the date that is eighteen (18) months after the Closing Date, at which
time they shall terminate (and no claims shall be made for indemnification under Section 9.02 or Section 9.03 thereafter), except: (i) the Fundamental Representations shall survive in
full force and effect until the date that is thirty (30) days after the expiration of the applicable statute of limitations and (ii) the covenants and agreements that by their terms apply or are to be performed in whole or in part
after the Closing shall survive for the period provided in such covenants and agreements, if any, or until fully performed. 

Section 9.02    Indemnification by the Issuer. 

(a)    After the Closing and subject to this Article IX, the Issuer shall indemnify, defend and
hold harmless the Buyer Indemnitees against, and reimburse the Buyer Indemnitees for, all Losses that the Buyer Indemnitees may at any time suffer or incur, or become subject to: 

        (i)    as a result of or in connection with the breach or
inaccuracy of any representation or warranty set forth in Article IV (other than a Fundamental Representation); 

        (ii)    as a result of or in connection with the breach or
inaccuracy of any Fundamental Representation; or 

        (iii)    as a result of or in connection with any breach or
failure by the Issuer to perform any of its covenants or obligations contained in this Agreement. 

(b)    Notwithstanding anything to the contrary contained herein, the Issuer shall not be required to indemnify, defend or
hold harmless the Buyer Indemnitees against, or reimburse the Buyer Indemnitees for, any Losses pursuant to Section 9.02(a)(i): (i) with respect to any claim (or series of related claims arising from similar
underlying facts, events or circumstances) unless such claim (or series of related claims) involves Losses in excess of $150,000 (nor shall any such claim or series of related claims that does not meet such $150,000 threshold be applied to or
considered for purposes of calculating the aggregate amount of the Buyer Indemnitees’ Losses for which the Issuer has responsibility under clause (ii) of Section 9.02(b) below); (ii) until the
aggregate amount of the Buyer Indemnitees’ Losses under Section 9.02(a)(i) exceeds $7,500,000, after which the Issuer shall be obligated for all the Buyer 

  
 32 

  

 
Indemnitee’s Losses under Section 9.02(a)(i) that are in excess of $7,500,000, but only if such excess Losses arise with respect to any claim (or series of related
claims) that involves Losses in excess of $150,000; and (iii) in a cumulative aggregate amount exceeding $50,000,000. For purposes of determining whether the threshold set forth in clause (iii) of this
Section 9.02(b) has been met or exceeded, any amount paid by the Issuer or any of its Affiliates for Losses pursuant to Section 9.02(a)(i) shall be taken into account. 

(c)    The Issuer shall not be required to indemnify, defend or hold harmless the Buyer Indemnitees against, or reimburse
the Buyer Indemnitees for, any Losses pursuant to Section 9.02(a) in a cumulative aggregate amount exceeding the Purchase Price. 

(d)    If, prior to the date hereof, the Buyer has Knowledge of any breach by the Issuer of any representation or warranty
contained in this Agreement, the Buyer shall be deemed to have waived such breach and the Buyer and the other Buyer Indemnitees shall not be entitled to indemnification pursuant to Section 9.02(a) to sue for Losses or to
assert any other right or remedy arising from any matters relating to such breach, notwithstanding anything to the contrary contained herein. 

Section 9.03    Indemnification by the Buyer. After the Closing and subject to this
Article IX, the Buyer shall indemnify, defend and hold harmless the Issuer Indemnitees against, and reimburse the Issuer Indemnitees for, all Losses that the Issuer Indemnitees may at any time suffer or incur, or become
subject to: 
         (i)    as a result of or in connection
with the breach or inaccuracy of any representation or warranty set forth in Article V; or 

        (ii)    as a result of or in connection with any breach or
failure by the Buyer to perform any of its covenants or obligations contained in this Agreement. 

Section 9.04    Claims Procedure. 

(a)    Notification by the Indemnified Party. If any Indemnified Party becomes aware of any fact, matter or
circumstance that may give rise to a claim for indemnification under this Article IX, the Indemnified Party shall (at its own expense) promptly notify the Indemnifying Party in writing of any claim in respect of which
indemnity may be sought under this Article IX, including any pending or threatened claim or demand against the Indemnified Party by a third party that the Indemnified Party has determined has given or could reasonably give
rise to a right of indemnification under this Agreement (including a pending or threatened claim or demand asserted by a third party against the Indemnified Party, a “Third Party Claim”), setting out the details of the claim, the
provisions under this Agreement on which such claim is based, its estimate of the amount of Losses to the extent ascertainable which are, or are to be, the subject of the claim and such other information (to the extent reasonably available) as is
reasonably necessary to enable the Indemnifying Party to assess the merits of the potential claim; provided, however, that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations under
this Article IX or otherwise affect the rights of any Indemnified Party except to the extent that the Indemnifying Party is actually prejudiced by such failure. The parties agree that (i) in this
Article IX they intend to shorten, in the case of the 

  
 33 

  

 
limited survival periods specified in Section 9.01, the applicable statute of limitations period with respect to certain indemnification claims hereunder,
(ii) notices for claims for indemnification in respect of a breach of a representation, warranty, covenant or agreement must be delivered prior to the expiration of the applicable survival period specified in
Section 9.01 for such representation, warranty, covenant or agreement and (iii) any claims for indemnification for which notice is not delivered prior to the expiration of the applicable survival period set
forth in Section 9.01 shall be expressly barred and are hereby waived; provided, further, that if, prior to such applicable date, a party hereto shall have notified the other party hereto in accordance with
the requirements of this Section 9.04(a) of a claim for indemnification under this Article IX (whether or not formal legal action shall have been commenced based upon such claim), such claim shall
continue to be subject to indemnification in accordance with this Article IX notwithstanding the passing of such applicable date. 

(b)    Cooperation by the Indemnified Party. The Indemnified Party shall reasonably cooperate with and assist the
Indemnifying Party in determining the validity of any claim for indemnity by the Indemnified Party and in defending against a Third Party Claim. 

(c)    The Indemnified Party shall not settle, compromise or consent to the entry of any judgment with respect to any
Third Party Claim or demand for which it is seeking indemnification from the Indemnifying Party or admit to any liability with respect to such Third Party Claim or demand without the prior written consent of the Indemnifying Party (which shall not
be unreasonably withheld, conditioned or delayed). Notwithstanding anything to the contrary contained in this Article IX, no Indemnifying Party shall have any liability under this Article IX for
any Losses arising out of or in connection with any Third Party Claim that is settled or compromised by an Indemnified Party without the consent of such Indemnifying Party. 

(d)    Assumption of Defense of a Third Party Claim. Upon receipt of a notice of a claim for indemnity from an
Indemnified Party pursuant to Section 9.04(a) in respect of a Third Party Claim, the Indemnifying Party may, by notice to the Indemnified Party delivered within thirty (30) Business Days of the receipt of notice of
such Third Party Claim, assume the defense and control of any Third Party Claim, with its own counsel and at its own expense, but shall allow the Indemnified Party to have a reasonable opportunity to participate in the defense of such Third Party
Claim with its own counsel and at its own expense. The Indemnifying Party shall be liable for the fees and expenses of counsel employed by the Indemnified Party (A) for any period during which the Indemnifying Party has not assumed the
defense of a Third Party Claim and (B) in connection with any claim where, based on the advice of outside counsel, a conflict in interest between the Indemnifying Party and the Indemnified Party exists. The Indemnifying Party shall not,
without the prior written consent of the Indemnified Party (which shall not be unreasonably withheld, conditioned or delayed), consent to a settlement, compromise or discharge of, or the entry of any judgment arising from, any Third Party Claim,
unless such settlement, compromise, discharge or entry of any judgment provides only for the payment of monetary damages (and does not impose any injunctive relief or otherwise impose any conditions or restrictions on the Indemnified Party) and does
not involve any finding or admission of any violation of Law or rights of any Person, admission of any wrongdoing, fault or culpability by the Indemnified Party, and the Indemnifying Party shall obtain, as a condition of any settlement, compromise,
discharge, entry of judgment (if applicable), or other resolution, a complete and unconditional release of each Indemnified Party from any and all liabilities in 

  
 34 

  

 
respect of such Third Party Claim. If the Indemnifying Party is controlling a defense of a Third Party Claim in accordance with this Article IX and fails to
defend diligently the action or proceeding after notifying the Indemnified Party of its assumption of the defense of such Third Party Claim, the Indemnified Party may assume such defense, and the reasonable and documented fees of its attorneys will
be covered by the indemnity provided for in this Article IX upon determination of the Indemnifying Party’s indemnity obligations. Notwithstanding anything to the contrary in this Section 9.04,
the Indemnified Party (and not the Indemnifying Party) shall have the exclusive right to assume the defense and control of any Third Party Claim if (A) the Indemnified Party in good faith determines that the nature of the Third Party
Claim is such that it would reasonably be expected to involve criminal liability being imposed on any Indemnified Party or its Affiliates or (B) such Third Party Claim seeks an injunction or other equitable relief against any Indemnified
Party; provided that if such Third Party Claim seeks an injunction or equitable relief against the Indemnified Party that can be separated from a related claim for money damages, the Indemnifying Party may only be entitled to assume control
of the defense of such Third Party Claim for money damages. 
 (e)    In the event any Indemnifying Party receives a
notice of a claim for indemnity from an Indemnified Party pursuant to Section 9.04(a) that does not involve a Third Party Claim, the Indemnifying Party shall notify the Indemnified Party within thirty (30) Business
Days following its receipt of such notice whether the Indemnifying Party disputes its liability to the Indemnified Party under this Article IX. 

Section 9.05    Payment. In the event a claim for indemnification under this
Article IX has been finally determined, the amount of such final determination shall be paid by the Indemnifying Party to the Indemnified Party on demand in immediately available funds. Any claim, action, suit, arbitration
or proceeding by or before any Governmental Authority or arbitral body, and the liability for and amount of damages therefor, shall be deemed to be “finally determined” for purposes of this Article IX when the
parties hereto have so determined by mutual agreement or, if disputed, when a final non-appealable Governmental Order has been entered into with respect to such claim, action, suit, arbitration or proceeding.

 Section 9.06    Treatment of Indemnification Payments. To the fullest extent permitted under applicable
Law, for all purposes (including Tax purposes), the parties hereto shall treat any payment made under Section 9.02 or Section 9.03 as an adjustment to the Purchase Price. 

Section 9.07    Provisions. No Indemnifying Party shall be liable under this
Article IX in respect of any Loss, if the fact, matter, event or circumstance giving rise to the claim or on which it is based is expressly accrued or reserved for in the Financial Statements. 

Section 9.08    Exclusive Remedies. Each party hereto acknowledges and agrees that, other than in the case of
actual fraud by a party to this Agreement in the making of a representation or warranty herein or willful breach by any party hereto, (a) prior to the Closing, the sole and exclusive remedy of the Buyer for any breach of any
representation or warranty set forth in Article IV shall be, in the event that each of the conditions set forth in Section 8.03 has not been satisfied or waived, refusal to close the purchase and
sale of the Purchased Shares and termination of this Agreement in accordance with Article X; (b) following the Closing, (i) the 

  
 35 

  

 
indemnification provisions of this Article IX shall be the sole and exclusive monetary remedies of the parties hereto for any breach of the representations or warranties
contained in this Agreement or any certificate or instrument delivered hereunder and (ii) notwithstanding anything to the contrary contained herein, no breach of any representation, warranty, covenant or agreement contained herein shall
give rise to any right on the part of any party hereto to rescind this Agreement or any of the transactions contemplated hereby; and (c) following the Closing, the indemnification provisions of this Article IX
shall be the sole and exclusive monetary remedies of the parties hereto for any breach or non-fulfillment of any covenant. 

Section 9.09    Damages. The Issuer and the Buyer agree that with respect to each indemnification obligation
set forth in this Article IX or any other document, instrument or certificate executed or delivered in connection with the Closing, in no event shall an Indemnifying Party have any liability to an Indemnified Party for:
(a) any punitive damages except to the extent paid to a third party and (b) special, consequential or indirect damages, in each case, to the extent not the reasonably foreseeable result of any breach by the Indemnifying Party
of a representation and warranty or covenant contained in this Agreement. For purposes of determining whether a breach of any representation or warranty made in this Agreement has occurred, and for calculating the amount of any Loss under this
Article IX, each representation and warranty contained in this Agreement shall be read without regard to any “materiality,” “Material Adverse Effect,” “Buyer Material Adverse Effect” or other
similar qualification contained in or otherwise applicable to such representation or warranty, other than the representation and warranty in Section 4.07(b). 

Section 9.10    Right to Recover. 

(a)    If the Indemnifying Party is liable to pay an amount in discharge of any claim under this Agreement and the
Indemnified Party recovers or is entitled to recover (whether by payment, discount, credit, relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Indemnified Party (in whole or in part) in respect of the
Losses which is the subject matter of the claim, then the Indemnified Party shall take such actions (at the Indemnifying Party’s sole cost and expense) as may be reasonably requested by the Indemnifying Party to enforce recovery against the
third party and any actual recovery (less any reasonable costs and expenses incurred in obtaining such recovery) shall reduce or satisfy, as the case may be, such claim to the extent of such recovery. Notwithstanding the foregoing, no party shall be
required to act or forbear to act under this Section 9.10 if such act or forbearance, as applicable, could prejudice such Person’s ability to prosecute a claim against the Indemnifying Party or any right hereunder in
the reasonable judgment of such party, as applicable. 
 (b)    If an Indemnifying Party has paid an amount in discharge
of any claim under this Agreement and the Indemnified Party recovers or is entitled to recover (whether by payment, discount, credit, relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Indemnified Party (in
whole or in part) in respect of the Loss which is the subject matter of the claim, then the Indemnified Party shall take such actions (at the Indemnifying Party’s sole cost and expense) as may be reasonably requested by the Indemnifying Party
to enforce such recovery and shall, or shall procure that the Indemnified Party shall pay to the Indemnifying Party, as soon as practicable after receipt an amount equal to (i) any sum recovered from the third party in respect of such
claim less any reasonable costs and expenses incurred in obtaining such recovery or (ii) if less, the amount previously paid by the Indemnifying Party to the Indemnified Party. 

  
 36 

  

 Section 9.11    Double Claims. No Indemnified Party shall be
entitled to recover from an Indemnifying Party under this Article IX for the same Losses more than once (notwithstanding that such Loss may result from breaches of multiple provisions of this Agreement). 

ARTICLE X 

TERMINATION AND WAIVER 

Section 10.01    Termination. This Agreement may be terminated prior to the Closing: 

(a)    by the mutual written consent of the Issuer and the Buyer; 

(b)    by either the Issuer or the Buyer if the Closing shall not have occurred prior to the date that is six
(6) months after the date of this Agreement (the “Outside Date”) or such later date as the parties may mutually agree; provided, however, that if the Closing has not occurred due solely to the
failure of the conditions to Closing set forth in Section 8.01(a) to be satisfied, the parties agree to extend the Outside Date for an additional ninety (90) days and continue to use their respective reasonable best
efforts to satisfy such Closing conditions (such extended Outside Date, as so extended, shall be the “Outside Date” for all purposes under this Agreement); provided, further, that the right to terminate this Agreement under
this 
Section 10.01(b) shall not be available to any party whose failure to take any action required to fulfill any of such party’s obligations under this Agreement shall have been the cause of, or shall have
resulted in, the failure of the Closing to occur prior to such date; 
 (c)    by either the Issuer or the Buyer in the
event of the issuance of a final, nonappealable Governmental Order from a Governmental Authority of competent jurisdiction prohibiting the consummation of the transactions contemplated by this Agreement; 

(d)    by the Buyer in the event of a breach by the Issuer of any of its covenants, representations or warranties
contained herein that would result in the conditions to the Closing set forth in Section 8.03 not being satisfied, and such breach is either not capable of being cured prior to the Outside Date or, if curable, the Issuer
shall have failed to cure such breach by the earlier of (i) sixty (60) days after receipt of written notice thereof from the Buyer requesting such breach to be cured and (ii) the Outside Date; 

(e)    by the Issuer in the event of a breach by the Buyer of any of the Buyer’s covenants, representations or
warranties contained herein that would result in the conditions to the Closing set forth in Section 8.02 not being satisfied, and such breach is either not capable of being cured prior to the Outside Date or, if curable,
the Buyer shall have failed to cure such breach by the earlier of (i) sixty (60) days after receipt of written notice thereof from the Issuer requesting such breach to be cured and (ii) the Outside Date. 

  
 37 

  

 Section 10.02    Notice of Termination. Any party desiring
to terminate this Agreement pursuant to Section 10.01 shall give written notice of such termination to the other party to this Agreement. 

Section 10.03    Effect of Termination. In the event of the termination of this Agreement as provided in
Section 10.01, this Agreement shall thereafter become void and there shall be no liability on the part of any party to this Agreement, except as set forth in Section 7.01, this
Article X and Article XI; provided that nothing in this Section 10.03 shall relieve the Issuer or the Buyer from liability for (a) failure to perform
its obligations set forth in Section 6.03 or (b) the actual fraud by a party to this Agreement in the making of a representation or warranty herein, willful breach of this Agreement or willful failure to perform
its respective obligations under this Agreement. 
 Section 10.04    Extension; Waiver. At any time prior to
the Closing, the Issuer and the Buyer may (a) extend the time for the performance of any of the obligations or other acts of the other parties, (b) waive any inaccuracies in the representations and warranties of the other
party contained in this Agreement or in any certificate, instrument, schedule or other document delivered pursuant to this Agreement or (c) waive compliance by the other party with any of the agreements or conditions contained in this
Agreement. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party granting such extension or waiver. 

ARTICLE XI 
 GENERAL
PROVISIONS 
 Section 11.01    Expenses. Except as may be otherwise specified in this Agreement, all
costs and expenses, including fees and disbursements of counsel, financial advisers and independent accountants, incurred in connection with this Agreement and the other Transaction Agreements and the transactions contemplated hereby and thereby
shall be paid by the Person incurring such costs and expenses, whether or not the Closing shall have occurred. 

Section 11.02    Notices. All notices, requests, consents, claims, demands and other communications under this
Agreement shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by electronic mail with receipt confirmed or by registered or certified
mail (postage prepaid, return receipt requested) to the respective parties at the following addresses, or at such other address for a party as shall be specified in a notice given in accordance with this Section 11.02: 

 

	 	(a)	 if to the Issuer: 

Brooke (Holdco1) Inc. 

1 Corporate Way 

Lansing, MI 48951 

Attention:      Thomas Hyatte 

E-mail:           
thomas.hyatte@jackson.com 

  
 38 

  

 with a copy to: 

Debevoise & Plimpton LLP 

919 Third Avenue 

New York, New York 10022 

Attention:      Nicholas F. Potter 

                      Marilyn A.
Lion 

E-mail:          
nfpotter@debevoise.com 

                      
malion@debevoise.com 
  

	 	(b)	 if to the Buyer: 

Athene Life Re Ltd. 

Chesney House 

96 Pitts Bay Road 

Pembroke HM08 Bermuda 

Attention:      Natasha Scotland Courcy 

E-mail:           
ncourcy@athene.bm 
 with a copy to: 

Sidley Austin LLP 

One South Dearborn 

Chicago, Illinois 60603 

Attention:      Perry J. Shwachman 

                      Jeremy C.
Watson 

E-mail:          
pshwachman@sidley.com 

                      
jcwatson@sidley.com 
 Section 11.03    Public Announcements. The initial press release with respect to the
Agreement and the transactions contemplated hereby shall be a joint press release in the form agreed by the Issuer and the Buyer and attached as Schedule 11.03. Thereafter, neither party to this Agreement or any Affiliate
or Representative of such party shall issue or cause the publication of any press release or public announcement or otherwise communicate with any news media in respect of this Agreement or the transactions contemplated by this Agreement without the
prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by Law or applicable securities exchange rules, in which case the party required to publish such press
release or public announcement shall allow the other party a reasonable opportunity to comment on such press release or public announcement in advance of such publication. 

Section 11.04    Severability. If any term or other provision of this Agreement is invalid, illegal or
incapable of being enforced under any Law or as a matter of public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions
contemplated by this Agreement is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced,

  
 39 

  

 
the parties to this Agreement shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated by this Agreement be consummated as originally contemplated to the greatest extent possible. 

Section 11.05    Entire Agreement. This Agreement (including all exhibits and schedules hereto), the other
Transaction Agreements and any other documents delivered pursuant hereto or thereto constitute the entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both
written and oral (other than the Confidentiality Agreement to the extent not in conflict with this Agreement and the Transaction Agreements), between or on behalf of the Issuer and its Affiliates, on the one hand, and the Buyer and its Affiliates,
on the other hand, with respect to the subject matter hereof and thereof. 
 Section 11.06    Assignment.
This Agreement shall not be assigned by either party hereto without the prior written consent of the other party; provided, that, following the Closing, the Buyer may, without the prior written consent of the Issuer, assign all or part of its
rights and obligations under this Agreement to one or more Permitted Transferees in connection with a transfer of Common Stock; provided, further, that no such assignment shall relieve the Buyer of any of its obligations hereunder. Any
attempted assignment in violation of this Section 11.06 shall be void. This Agreement shall be binding upon, shall inure to the benefit of, and shall be enforceable by, the parties hereto and their permitted successors and
assigns. 
 Section 11.07    No Third-Party Beneficiaries. Except as provided in
Article IX with respect to the Buyer Indemnitees or the Issuer Indemnitees, this Agreement is for the sole benefit of the parties to this Agreement and their permitted successors and assigns and nothing in this Agreement,
express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 

Section 11.08    Amendment. No provision of this Agreement may be amended, supplemented or modified except by
a written instrument signed by all the parties hereto. 
 Section 11.09    Schedules. Any disclosure set
forth in the Disclosure Schedule with respect to any Section of this Agreement shall be deemed to be disclosed for purposes of other Sections of this Agreement to the extent that such disclosure sets forth facts in sufficient detail so that the
relevance of such disclosure would be reasonably apparent to a reader of such disclosure. Matters reflected in any Section of the Disclosure Schedule are not necessarily limited to matters required by this Agreement to be so reflected. Such
additional matters are set forth for informational purposes and do not necessarily include other matters of a similar nature. No reference to or disclosure of any item or other matter in the Disclosure Schedule shall be construed as an admission or
indication that such item or other matter is material or that such item or other matter is required to be referred to or disclosed in this Agreement. Without limiting the foregoing, no such reference to or disclosure of a possible breach or
violation of any contract, Law or Governmental Order shall be construed as an admission or indication that a breach or violation exists or has actually occurred. 

  
 40 

  

 Section 11.10    Submission to Jurisdiction. 

(a)    The Issuer and the Buyer each irrevocably and unconditionally submit for itself and its property in any Action
arising out of or relating to this Agreement, the transactions contemplated hereby, the formation, breach, termination or validity of this Agreement or the recognition and enforcement of any judgment in respect of this Agreement, to the exclusive
jurisdiction of the courts of the State of New York sitting in the County of New York, the federal courts for the Southern District of New York and appellate courts having jurisdiction of appeals from any of the foregoing, and all claims in respect
of any such Action shall be heard and determined in such New York courts or, to the extent permitted by Law, in such federal court. 

(b)    Any such Action may and shall be brought in such courts and each of the Issuer and the Buyer irrevocably and
unconditionally waives any objection that it may now or hereafter have to the venue or jurisdiction of any such Action in any such court or that such Action was brought in an inconvenient court and shall not plead or claim the same. 

(c)    Service of process in any Action may be effected by mailing a copy of such process by registered or certified mail
(or any substantially similar form of mail), postage prepaid, to such party at its address as provided in Section 11.02. 

(d)    Nothing in this Agreement shall affect the right to effect service of process in any other manner permitted by the
Laws of the State of New York. 
 Section 11.11    Governing Law. This Agreement, and the formation,
termination or validity of any part of this Agreement shall in all respects be governed by, and construed in accordance with, the Laws of the State of New York, without regard to any conflict of laws principles. 

Section 11.12    Waiver of Jury Trial. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY ACTION (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, OR ITS PERFORMANCE UNDER OR THE ENFORCEMENT OF THIS AGREEMENT. 

Section 11.13    Specific Performance. The parties agree that irreparable damage would occur in the event that
any of the covenants or obligations contained in this Agreement are not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the parties hereto shall be entitled to injunctive or other equitable relief
to prevent or cure any breach by the other parties of its covenants or obligations contained in this Agreement and to specifically enforce such covenants and obligations in any court referenced in Section 11.10(a) having
jurisdiction, such remedy being in addition to any other remedy to which any party may be entitled at law or in equity. The parties acknowledge and agree that, in the event that the other parties seek an injunction or injunctions to prevent breaches
of this Agreement or to enforce specifically the terms and provisions of this Agreement, the party seeking an injunction will not be required to provide any bond or other security in connection with any such order or injunction. 

  
 41 

  

 Section 11.14    Waivers. Any term or provision of this
Agreement may be waived, or the time for its performance may be extended, in writing at any time by the party entitled to the benefit thereof. Any such waiver shall be validly and sufficiently authorized for the purposes of this Agreement if, as to
any party, it is authorized in writing by an authorized Representative of such party. The failure of any party hereto to enforce at any time any provision of this Agreement shall not be construed to be a waiver of such provision, nor in any way to
affect the validity of this Agreement or any part hereof or the right of any party thereafter to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to constitute a waiver of any preceding or subsequent
breach. 
 Section 11.15    Rules of Construction. Interpretation of this Agreement shall be governed by the
following rules of construction: (a) words in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires; (b) references to
Articles, Sections, paragraphs, Exhibits and Schedules are references to the Articles, Sections, paragraphs, Exhibits and Schedules to this Agreement unless otherwise specified; (c) references to “$” shall mean United
States dollars; (d) the word “including” and words of similar import when used in this Agreement shall mean “including without limiting the generality of the foregoing,” unless otherwise specified;
(e) the word “or” shall not be exclusive, (f) the table of contents, articles, titles and headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement; (g) this Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting or causing any instrument to be drafted;
(h) the Schedules and Exhibits referred to herein shall be construed with and as an integral part of this Agreement to the same extent as if they were set forth verbatim herein; (i) unless the context otherwise requires, the
words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement;
(j) all terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein; (k) any agreement or instrument
defined or referred to herein or any agreement or instrument that is referred to herein means such agreement or instrument as from time to time amended, modified or supplemented, including by waiver or consent, and references to all attachments
thereto and instruments incorporated therein; (l) any statement that a document has been “delivered,” “provided” or “made available” to the Buyer means that such document has been uploaded to the Electronic
Data Room (and thereafter remain posted in the Electronic Data Room at all times) not later than three (3) Business Days prior to the date of this Agreement; (m) any statute or regulation referred to herein means such statute or
regulation as amended, modified, supplemented or replaced from time to time (and, in the case of any statute, includes any rules and regulations promulgated under such statute), and references to any section of any statute or regulation include any
successor to such section; (n) all time periods within or following which any payment is to be made or act to be done shall be calculated by excluding the date on which the period commences and including the date on which the period ends
and by extending the period to the first succeeding Business Day if the last day of the period is not a Business Day; (o) references to any Person include such Person’s predecessors or successors, whether by merger, consolidation,
amalgamation, reorganization or otherwise; and (p) references to any contract (including this Agreement) or organizational document are to the contract or organizational document as amended, modified, supplemented or replaced from time
to time, unless otherwise stated. 

  
 42 

  

 Section 11.16    Reserves. Notwithstanding anything to the
contrary in this Agreement, neither the Issuer nor any of its Affiliates makes any representation or warranty with respect to, and nothing contained in this Agreement or in any other agreement, document or instrument to be delivered in connection
with the transactions contemplated hereby is intended or shall be construed to be a representation or warranty (express or implied) of the Issuer or any of its Affiliates, for any purpose of this Agreement or any other agreement, document or
instrument to be delivered in connection with the transactions contemplated hereby or thereby, with respect to (a) the adequacy or sufficiency of the reserves of the Insurance Companies or (b) the future profitability of the
Business. Furthermore, no fact, condition, circumstance or event relating to or affecting the sufficiency of the reserves of the Insurance Companies may be used, directly or indirectly, to demonstrate or support the breach of any representation,
warranty, covenant or agreement contained in this Agreement, any other Transaction Agreement or any other agreement, document or instrument to be delivered in connection with this Agreement or the other Transaction Agreements. 

Section 11.17    Counterparts. This Agreement may be executed by the parties to this Agreement in separate
counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or
electronic mail shall be as effective as delivery of a manually executed counterpart of this Agreement. 
 [THE REMAINDER OF THIS PAGE
INTENTIONALLY LEFT BLANK] 

  
 43 

  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the date first
written above by their respective duly authorized officers. 
  

			
	BROOKE (HOLDCO1) INC.
		
	By:	 	 /s/ Michael A. Costello

			
	Name:	 	Michael A. Costello
	Title:	 	President and Treasurer
	
	ATHENE LIFE RE LTD.

 
			
		
	By:	 	 /s/ Adam Laing

 

			
	Name:	 	Adam Laing
	Title:	 	Chief Financial Officer

 [Signature Page to Investment Agreement]EX-10.4

 Exhibit 10.4 

EXECUTION VERSION 
 STOCKHOLDERS
AGREEMENT 
 OF 

JACKSON FINANCIAL INC. 

dated as of July 17, 2020 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 	 	ARTICLE I	  	 	 
			
	 	 	DEFINITIONS	  	 	 
			
	 Section 1.1.
	 	 Certain Defined Terms
	  	 	1	 
	 Section 1.2.
	 	 Other Definitional Provisions
	  	 	8	 
	 Section 1.3.
	 	 Methodology for Calculations
	  	 	8	 
			
	 	 	ARTICLE II	  	 	 
			
	 	 	CORPORATE GOVERNANCE	  	 	 
			
	 Section 2.1.
	 	 Board
	  	 	8	 
	 Section 2.2.
	 	 Removal
	  	 	10	 
	 Section 2.3.
	 	 Voting
	  	 	10	 
	 Section 2.4.
	 	 Consent Rights
	  	 	10	 
	 Section 2.5.
	 	 Financial Information
	  	 	12	 
	 Section 2.6.
	 	 Termination of Rights Upon IPO
	  	 	12	 
			
	 	 	ARTICLE III	  	 	 
			
	 	 	TRANSFERS	  	 	 
			
	 Section 3.1.
	 	 Restrictions on Transfer
	  	 	13	 
	 Section 3.2.
	 	 Right of First Refusal
	  	 	14	 
	 Section 3.3.
	 	 Tag-Along Right
	  	 	16	 
	 Section 3.4.
	 	 Drag-Along Right
	  	 	19	 
	 Section 3.5.
	 	 IPO Cooperation
	  	 	21	 
			
	 	 	ARTICLE IV	  	 	 
			
	 	 	EQUITY PURCHASE RIGHTS	  	 	 
			
	 Section 4.1.
	 	 Equity Purchase Rights
	  	 	22	 
	 Section 4.2.
	 	 Termination of Equity Purchase Rights
	  	 	23	 
			
	 	 	ARTICLE V	  	 	 
			
	 	 	MISCELLANEOUS	  	 	 
			
	 Section 5.1.
	 	 Certificate of Incorporation and By-Laws
	  	 	23	 
	 Section 5.2.
	 	 Termination
	  	 	23	 
	 Section 5.3.
	 	 Confidentiality
	  	 	23	 

  
 i 

							
	 Section 5.4.
	 	 Amendments
	  	 	24	 
	 Section 5.5.
	 	 Successors, Assigns and Transferees
	  	 	24	 
	 Section 5.6.
	 	 Notices
	  	 	24	 
	 Section 5.7.
	 	 Further Assurances
	  	 	26	 
	 Section 5.8.
	 	 Entire Agreement; Third Party Beneficiaries
	  	 	26	 
	 Section 5.9.
	 	 Restrictions on Other Agreements
	  	 	26	 
	 Section 5.10.
	 	 Delays or Omissions
	  	 	27	 
	 Section 5.11.
	 	 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial
	  	 	27	 
	 Section 5.12.
	 	 Specific Performance
	  	 	28	 
	 Section 5.13.
	 	 Severability
	  	 	28	 
	 Section 5.14.
	 	 Titles and Subtitles
	  	 	28	 
	 Section 5.15.
	 	 No Recourse
	  	 	28	 
	 Section 5.16.
	 	 Counterparts; Facsimile Signatures
	  	 	28	 
			
	 	 	ARTICLE VI	  	 	 
			
	 	 	REPRESENTATIONS AND WARRANTIES	  	 	 
			
	 Section 6.1.
	 	 Representations and Warranties of the Stockholders
	  	 	29	 

  
 ii 

 THIS STOCKHOLDERS AGREEMENT (as amended, supplemented or otherwise modified from time to
time, this “Agreement”) is entered as of July 17, 2020, by and among Jackson Financial Inc., a Delaware corporation (the “Company”), Prudential (US Holdco 1) Limited, a UK limited company
(“Parent”), Athene Life Re Ltd., a Bermuda Class E insurer under the Bermuda Insurance Act 1978 (“Kate Investor”), and any Person who becomes a party hereto after the date hereof pursuant to
Section 3.1(c) (each of the foregoing, excluding the Company, a “Stockholder” and collectively, the “Stockholders”). 

RECITALS 
 WHEREAS,
immediately prior to the date hereof, Parent owned all of the issued and outstanding capital stock of the Company; 
 WHEREAS, the Company
(formerly, Brooke (Holdco1) Inc.) and Kate Investor have entered into an Investment Agreement, dated as of June 18, 2020 (as amended, supplemented or otherwise modified from time to time, the “Investment Agreement”), pursuant
to which the Company issued and sold to Kate Investor, and Kate Investor purchased from the Company (the “Investment”), eighty-seven (87) shares of the Company’s Class A Common Stock, par value $0.01 per share (the
“Class A Common Stock”) and thirteen (13) shares of the Company’s Class B Common Stock, par value $0.01 per share (the “Class B Common Stock”); 

WHEREAS, the Company and Kate Investor have entered into a Registration Rights Agreement, dated as of the date hereof (the
“Registration Rights Agreement”), pursuant to which certain registration rights have been granted to Kate Investor, upon the terms and subject to the conditions set forth in the Registration Rights Agreement; and 

WHEREAS, in connection with the Investment, the Company and the Stockholders desire to set forth certain terms and conditions regarding the
ownership of Equity Securities, including certain restrictions on the Transfer of such securities, and the management of the Company and its Subsidiaries. 

NOW, THEREFORE, in consideration of the foregoing recitals and of the mutual promises hereinafter set forth, the parties hereto agree as
follows: 
 ARTICLE I 

DEFINITIONS 

SECTION 1.1.    Certain Defined Terms. As used herein, the following terms shall have the following meanings:

 “Affiliate” means, with respect to any specified Person, any other Person that, at the time of determination, directly
or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such specified Person; provided, that in no event shall (i) any pooled investment vehicle, fund, managed account or other
client to which Apollo Global Management, Inc. or any of its respective Affiliates or Subsidiaries provides investment advice or otherwise serves in a fiduciary capacity or (ii) any portfolio company in which the entities described in
clause (i) directly or indirectly hold investments be deemed an Affiliate of Kate Investor. 

 “Agreement” has the meaning assigned to such term in the preamble. 

“beneficial owner” or “beneficially own” has the meaning assigned such term in Rule 13d-3 under the Exchange Act, and a Person’s beneficial ownership of Common Stock or other Equity Securities of the Company shall be calculated in accordance with the provisions of such Rule, but without taking
into account any contractual restrictions or limitations on voting or other rights; provided, however, that for purposes of determining beneficial ownership, (i) a Person shall be deemed to be the beneficial owner of any
security which may be acquired by such Person, whether within sixty (60) days or thereafter, upon the conversion, exchange or exercise of any warrants, options, rights or other securities and (ii) no Person shall be deemed to
beneficially own any security solely as a result of such Person’s execution of this Agreement. 
 “Board” means the
Board of Directors of the Company. 
 “Business Day” means any day that is not a Saturday, Sunday or other day on which
commercial banks in Lansing, Michigan or New York, New York are required or authorized by Law to remain closed. 
 “By-Laws” means the By-Laws of the Company, as amended from time to time. 

“CEO” means the Chief Executive Officer of the Company in office from time to time. 

“Certificate of Incorporation” means the Certificate of Incorporation of the Company, as amended from time to time. 

“Class A Common Stock” has the meaning assigned to such term in the recitals. 

“Class B Common Stock” has the meaning assigned to such term in the recitals. 

“Closing” means the closing pursuant to the Investment Agreement. 

“Closing Date” means July 17, 2020. 

“Code” means the United States Internal Revenue Code of 1986. 

“Common Stock” means the Company’s common stock, par value $0.01 per share, including the Class A Common Stock and
the Class B Common Stock. 
 “Common Stock Equivalent” means all options, warrants and other securities convertible
into, or exchangeable or exercisable for (at any time or upon the occurrence of any event or contingency and without regard to any vesting or other conditions to which such securities may be subject) shares of Common Stock or other equity securities
of the Company (including any notes or other debt securities convertible into or exchangeable for shares of Common Stock or other equity securities of the Company). 

  
 2 

 “Company” has the meaning assigned to such term in the preamble. 

“Competitor” means the Persons listed on Schedule 1.1; provided that the Company shall be permitted to update Schedule
1.1 from time to time after the date hereof to add any Persons that the Board reasonably and in good faith determines have become competitors of the Company in the U.S. retirement product sector, in which case the updated Schedule 1.1 shall be
deemed to replace the version of Schedule 1.1 then in effect with no consent or action required on behalf of any of the Stockholders. 

“control” means, with respect to any Person, the power to direct or cause the direction of the management and policies of
such Person, whether through the ownership of voting securities, by contract or otherwise. The terms “controlled,” “controlled by,” “under common control with” and “controlling”
shall have correlative meanings. 
 “DGCL” means the Delaware General Corporation Law, as amended from time to time. 

“Director” means any member of the Board. 

“Dragged Stockholder” has the meaning assigned to such term in Section 3.4(a). 

“Drag-Along Notice” has the meaning assigned to such term in Section 3.4(e). 

“Drag-Along Transaction” has the meaning assigned to such term in Section 3.4(a). 

“Equity Securities” means (i) any and all shares of Common Stock or other equity securities of the Company and
(ii) any and all options, warrants and other securities convertible into, or exchangeable or exercisable for (at any time or upon the occurrence of any event or contingency and without regard to any vesting or other conditions to which
such securities may be subject) such shares or other equity securities of the Company (including any notes or other debt securities convertible into or exchangeable for such shares or other equity securities of the Company). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 “Exiting Stockholder” has the meaning assigned to such term in Section 3.4(a). 

“Fair Market Value” means the fair market value of any specified securities or other assets as determined in good faith by
the Board (or any committee authorized by the Board). 
 “GAAP” means generally accepted accounting principles, as in
effect in the United States of America from time to time. 

  
 3 

 “Governmental Body” means any domestic or foreign government, including any
foreign, federal, state, provincial, local, territorial or municipal government or any governmental division, agency or authority thereof, court or judicial authority, tribunal or commission. 

“Information” means all information about the Company, any of its Subsidiaries or any Stockholder or Affiliate thereof that
is or has been furnished to any Stockholder or any of its Representatives by or on behalf of the Company or any of its Subsidiaries, or any of their respective Representatives, and any other information supplied by or relating to the Company, its
Subsidiaries or any Stockholder in connection with the matters contemplated by the Investment Agreement or any other Transaction Agreement (in any such case, whether written or oral or in electronic or other form and whether prepared by the Company,
its advisers or otherwise), together with all written or electronically stored documentation prepared by such Stockholder or its Representatives based on or reflecting, in whole or in part, such information; provided that the term
“Information” does not include any information that (i) is or becomes generally available to the public through no action or omission by such Stockholder or its Representatives in violation of this Agreement,
(ii) is or becomes available to such Stockholder on a non-confidential basis from a source, other than the Company or any of its Subsidiaries, or any of their respective Representatives, that to
such Stockholder’s knowledge, is not prohibited from disclosing such portions to such Stockholder by a contractual, legal or fiduciary obligation, (iii) is independently developed by a Stockholder or its Representatives or
Affiliates on its own behalf without use of any Information or (iv) is provided to Kate Investor or its Permitted Transferees or Affiliates in connection with the Kate Investor’s reinsurance agreement with Jackson National Life
Insurance Company (which shall be governed by such reinsurance agreement). 
 “Investment” has the meaning assigned to such
term in the recitals. 
 “Investment Agreement” has the meaning assigned to such term in the recitals. 

“IPO” means a firm commitment underwritten public offering pursuant to an effective registration statement under the
Securities Act, demerger, spin-off, split-off, direct listing, or other similar transaction that results in the public listing of any Equity Securities or any equity
securities of a direct or indirect parent of the Company (other than Prudential plc). 
 “Issuance Notice” has the meaning
assigned to such term in Section 4.1(b). 
 “Kate Investment Vehicle” means any investment fund,
investment vehicle or holding company in which Athene Holding Ltd. or any of its Subsidiaries holds an economic interest and which investment fund, investment vehicle or holding company is primarily invested in insurance-related businesses. 

“Kate Investor” has the meaning assigned to such term in the preamble. 

“Kate Observer” has the meaning assigned to such term in Section 2.1(b). 

“Law” means any foreign, federal, state or local law, statute, regulation, ordinance, rule, order, decree, judgment, consent
decree or other binding directive issued, enacted, promulgated, entered into, agreed or imposed by any Governmental Body. 

  
 4 

 “New Securities” means any Equity Securities or any Subsidiary Equity
Securities issued by the Company or any Subsidiary of the Company following the Closing, other than (i) Equity Securities or Subsidiary Equity Securities issued to employees or officers (including any Equity Securities or Subsidiary
Equity Securities issued upon exercise of options) pursuant to a management incentive plan or any other stock option, employee stock purchase or similar equity-based plans (including the purchase of Common Stock by management stockholders (for the
avoidance of doubt, other than Directors) following the Closing as part of a management offering made pursuant to Section 701 of the Securities Act or another exemption from registration under the Securities Act) approved by the Board,
(ii) Equity Securities or Subsidiary Equity Securities issued solely as consideration for a bona fide third party acquisition, investment involving the purchase by the Company and its Subsidiaries of a ten percent (10%) or more
interest in a third party, joint venture or similar transaction, in each case that is duly approved by the Board (or the applicable Subsidiary’s board of directors or equivalent governing body), (iii) Equity Securities or Subsidiary
Equity Securities issued pursuant to an IPO, (iv) Equity Securities or Subsidiary Equity Securities issued in connection with a pro rata stock split, stock dividend or similar transaction, (v) shares of Common Stock
issued to Kate Investor or its Permitted Transferees, (vi) Equity Securities or Subsidiary Equity Securities issued upon the exercise or conversion of any Common Stock Equivalents (or the equivalent with respect to any Company
Subsidiary) where such Common Stock Equivalents were the subject of an Issuance Notice under Section 4.1 and (vii) Subsidiary Equity Securities issued to the Company or another wholly owned Subsidiary of the
Company. 
 “Outstanding Capital Shares” means, at any time, the total number of shares of Common Stock issued and
outstanding as of such time. 
 “Parent” has the meaning assigned to such term in the preamble. 

“Permitted Transferee” means, with respect to Kate Investor and its Permitted Transferees, (i) any Affiliate of Kate
Investor and (ii) any Kate Investment Vehicle; provided that any such Transferee satisfies the conditions set forth in Section 3.1(c); provided, further, that in no event shall the Company or any
of its Subsidiaries constitute a “Permitted Transferee” of Kate Investor or its Permitted Transferees. 

“Person” means any natural person, partnership, limited liability company, corporation, joint stock company, trust, estate,
joint venture, group, association or unincorporated organization or any other form of business or professional entity, but does not include a Governmental Body. 

“Preemptive Rights Recipients” has the meaning assigned to such term in Section 4.1(a). 

“Pro Rata Portion” means: 

        (i)    for purposes of
Section 3.3(c), with respect to the Tag-Along Participants in the aggregate or the Transferring Stockholder, the number of Equity Securities equal to the product of
(A) the total number of Equity Securities to be Transferred to the proposed Transferee that the proposed Transferee has elected to 

  
 5 

 
purchase and (B) the fraction determined by dividing (x) the total number of shares of Common Stock proposed to be Transferred by all of the
Tag-Along Participants in the aggregate (up to the number of shares of Common Stock representing such Tag-Along Participants’
Tag-Along Percentage) or the Transferring Stockholder, as applicable, by (y) the total number of shares of Common Stock proposed to be Transferred by (1) all of the Tag-Along Participants who have delivered Tag-Along Acceptance Notices with respect to such shares of Common Stock in response to the particular Transfer Notice (up to the
number of shares of Common Stock representing such Tag-Along Participants’ Tag-Along Percentage), (2) the Transferring Stockholder and (3) any
employees of the Company or its Subsidiaries who are entitled to tag-along rights pursuant to the terms of any applicable equity award grant, management incentive plan or any management stockholder agreement
with the Company, in each case that is approved by the Board, to which such employee is a party and who have elected to participate in such Transfer; and 

        (ii)    for purposes of
Section 4.1, with respect to the Preemptive Rights Recipients in the aggregate, on any date on which an allocation is made by the Company, the number of New Securities equal to the product of (A) the total
number of New Securities being allocated and (B) the fraction determined by dividing (x) the number of Outstanding Capital Shares beneficially owned by all Preemptive Rights Recipients on the date on which such allocation is
made by the Company by (y) the total number of Outstanding Capital Shares as of such date. 
 “Purchase Offer”
has the meaning assigned to such term in Section 3.2(b). 
 “Registration Rights Agreement” has
the meaning assigned to such term in the recitals. 
 “Representatives” means with respect to any Person, any of such
Person’s, or its Affiliates’, directors, officers, employees, general partners, Affiliates, direct or indirect shareholders, members or limited partners, attorneys, accountants, financial and other advisers, and other agents and
representatives. 
 “ROFR Exercise Period” has the meaning assigned to such term in
Section 3.2(c). 
 “ROFR Initiator” has the meaning assigned to such term in
Section 3.2(a). 
 “ROFR Initiator Notice” has the meaning assigned to such term in
Section 3.2(b). 
 “ROFR Notice” has the meaning assigned to such term in
Section 3.2(c). 
 “ROFR Proposed Transfer” has the meaning assigned to such term in
Section 3.2(a). 
 “SEC” means the United States Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

  
 6 

 “Stockholder” has the meaning assigned to such term in the preamble. 

“Subsidiary” of any Person means any corporation, general or limited partnership, joint venture, limited liability company,
limited liability partnership or other Person that is a legal entity, trust or estate of which (or in which) at the time of determination (a) the issued and outstanding capital stock having ordinary voting power to elect a majority of
the board of directors (or a majority of another body performing similar functions) of such corporation or other Person (irrespective of whether at the time capital stock of any other class or classes of such corporation or other Person shall or
might have voting power upon the occurrence of any contingency), (b) more than fifty percent (50%) of the interest in the capital or profits of such partnership, joint venture or limited liability company or (c) more than
fifty percent (50%) of the beneficial interest in such trust or estate, is directly or indirectly owned by such Person. 

“Subsidiary Equity Securities” means (i) any and all shares of capital stock or other equity securities of any
Subsidiary of the Company and (ii) any and all options, warrants and other securities convertible into, or exchangeable or exercisable for (at any time or upon the occurrence of any event or contingency and without regard to any vesting
or other conditions to which such securities may be subject), such shares or other equity securities of such Subsidiary of the Company (including any notes or other debt securities convertible into or exchangeable for such shares or other equity
securities of such Subsidiary of the Company). 
 “Tag-Along Acceptance Notice” has
the meaning assigned to such term in Section 3.3(c). 
 “Tag-Along
Participants” has the meaning assigned to such term in Section 3.3(a). 
 “Tag-Along Percentage” has the meaning assigned to such term in Section 3.3(c). 

“Tag-Along Securities” has the meaning assigned to such term in
Section 3.3(b). 
 “Tag-Along Transaction” has the
meaning assigned to such term in Section 3.3(a). 
 “Third-Party Offeror” has the meaning
assigned to such term in Section 3.2(b). 
 “Transaction Agreements” means, collectively, this
Agreement, the Investment Agreement and the Registration Rights Agreement. 
 “Transfer” means, directly or indirectly, to
sell, transfer, assign, pledge, encumber, hypothecate or similarly dispose of, either voluntarily or involuntarily, or to enter into any contract, option or other arrangement or understanding with respect to the sale, transfer, assignment, pledge,
encumbrance, hypothecation or similar disposition of, any shares of Equity Securities beneficially owned by a Person or any interest in any shares of Equity Securities beneficially owned by a Person. The noun “Transfer” has a meaning
correlative to the foregoing. 
 “Transfer Notice” has the meaning assigned to such term in
Section 3.3(b). 

  
 7 

 “Transfer Price” has the meaning assigned to such term in
Section 3.2(b). 
 “Transfer Shares” has the meaning assigned to such term in
Section 3.2(b). 
 “Transferee” means any Person to whom any Stockholder Transfers Equity
Securities in accordance with the terms hereof. 
 “Transferring Stockholder” has the meaning assigned to such term in
Section 3.3(a). 
 SECTION 1.2.    Other Definitional Provisions. The words
“hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Article and Section
references are to this Agreement unless otherwise specified. The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms. The use of the terms “including” or
“include” shall in all cases herein mean “including, without limitation” or “include, without limitation,” respectively. 

SECTION 1.3.    Methodology for Calculations. 

(a)    Except as otherwise expressly provided herein, any Transfer or proposed Transfer of a Common Stock Equivalent shall
be treated as a Transfer or proposed Transfer of the shares of Common Stock into or for which such Common Stock Equivalent can be converted, exchanged or exercised. 

(b)    Except as otherwise expressly provided in this Agreement, for purposes of calculating (i) the total
number of Outstanding Capital Shares as of any date or (ii) the number of Outstanding Capital Shares owned by any Person hereunder as of any date, no Common Stock Equivalents shall be treated as having been converted, exchanged or
exercised. 
 (c)    In the event of any stock split, stock dividend, reverse stock split, any combination of Equity
Securities or any similar event, with respect to all references in this Agreement to a Stockholder or Stockholders holding a number of Outstanding Capital Shares, the applicable amount shall be appropriately adjusted to give effect to such stock
split, stock dividend, reverse stock split, any combination of the Equity Securities or similar event. 
 ARTICLE II 

CORPORATE GOVERNANCE 

SECTION 2.1.    Board. 

(a)    Board Composition. The total number of Directors constituting the full Board shall initially be nine (9). The
initial composition of the Board shall be as follows: 

        (i)    eight (8) Directors designated by the holders
of Common Stock entitled to vote in the election of Directors, as a group, who initially shall be Axel André, Bradley O. Harris, Kenneth H. Stewart, Aimee R. DeCamillo, Michael Wells, Mark FitzPatrick, James Turner and Adrian Parkes; and 

  
 8 

        (ii)    the CEO, who initially shall be Michael Falcon.

 (b)    Observer Right. Subject to Section 2.1(c), for so long as Kate Investor
(together with its Permitted Transferees) beneficially owns in the aggregate a number of Outstanding Capital Shares representing at least eight percent (8%) of the number of Outstanding Capital Shares on a fully diluted basis, Kate Investor shall
have the right to designate one (1) individual (such designee or its replacement pursuant to this Article II, as applicable, the “Kate Observer”) to attend in person or join telephonically all meetings of the Board and
the audit committee and risk committee thereof in a non-voting, observer capacity. The Kate Observer shall be given notice of all meetings of the Board, including all audit committee and risk committee
meetings, in substantially the same manner and at substantially the same time as notice is sent to the members of the Board or such committee, as the case may be, and shall receive a copy of all notices, agendas and other material information
distributed to all the members of the Board or such committee in substantially the same manner and at substantially the same time as sent to the members of the Board or such committee, as the case may be; provided, however, that such
Kate Observer shall enter into a mutually acceptable customary confidentiality agreement with the Company with respect to all information so provided; provided further, that the Company reserves the right to withhold any information
and to exclude any Kate Observer from the applicable portion of a meeting if the Company’s general counsel determines in good faith that access to such information or attendance at such portion of the meeting would reasonably be expected to
result in (A) a loss of an attorney-client privilege or attorney work product protection, (B) disclosure of trade secrets or competitively sensitive information relating to the Company’s or a Company Subsidiary’s
business, or (C) a conflict of interest (including information or meetings with respect to any action to be taken, or any determination to be made, by the Board or a committee thereof regarding any dispute with Kate Investor (or any of
its Permitted Transferees or Affiliates)); provided, further, that, with respect to clauses (A)-(C), the Company uses reasonable efforts, and cooperates in good faith with Kate Investor, to develop and implement
reasonable alternative arrangements to provide Kate Investor with the intended benefits of this Section 2.1(b). Upon Kate Investor (together with its Permitted Transferees) ceasing to beneficially own in the aggregate a
number of Outstanding Capital Shares representing at least eight percent (8%) of the number of Outstanding Capital Shares on a fully diluted basis, the Kate Observer shall immediately cease attending meetings of the Board and the audit committee and
risk committee thereof, and all rights of Kate Investor and obligations of the Company and the Stockholders, in each case with respect to any Kate Observer pursuant to this Article II, shall terminate. 

(c)    Objection to Kate Observer. Notwithstanding the provisions of this Article II, Kate Investor shall
not be entitled to designate a Kate Observer pursuant to Section 2.1(b) in the event that the Board reasonably determines that (i) such designation would cause the Company to not be in compliance with applicable Law, (ii) such designee is a
director, officer, employee or Affiliate of, or an equityholder (directly or indirectly) of more than 5% of the ownership interests in, a Competitor of the Company and (iii) such designee comports himself of herself in a manner inconsistent with the
reasonable standards of conduct imposed on all members of the Board. In any such case described in clause (i), (ii) or (iii) of the immediately 

  
 9 

 
preceding sentence, Kate Investor shall withdraw the designation of such proposed designee and, subject to Section 2.1(b), shall be permitted to designate a replacement
therefor (which replacement designee shall also be subject to the requirements of this Section 2.1(c)). 

SECTION 2.2.    Removal. Upon the written request of a majority-in-interest of the holders of Common Stock with respect to a Director designated by the holders of Common Stock, each Stockholder shall vote, or act by written consent with respect to, all Equity
Securities beneficially owned by it that are entitled to vote in the election of Directors, and shall otherwise take or cause to be taken all actions necessary, to remove any Director designated by the holders of Common Stock pursuant to
Section 2.1 and to elect any replacement Director designated. 

SECTION 2.3.    Voting.    Subject to applicable Law, each of the Stockholders agrees to
vote, or act by written consent with respect to, any Equity Securities beneficially owned by it that are entitled to vote in the election of Directors, at each annual or special meeting of stockholders of the Company at which Directors are to be
elected, or to take all actions by written consent in lieu of any such meeting as are necessary, to cause any Directors designated in accordance with Section 2.1 to be elected to the Board. At each meeting of the
stockholders of the Company and at every postponement or adjournment thereof, Kate Investor and its Permitted Transferees shall take such action (including by written consent) as may be required so that all of the shares of Common Stock beneficially
owned, directly or indirectly, by such Person and entitled to vote at such meeting of stockholders of the Company are voted (i) in favor of each director nominated and recommended by the Board for election at any such meeting and
(ii) against any stockholder nominations for director which are not approved and recommended by the Board for election. Kate Investor agrees to cause each share of Common Stock beneficially owned by it or its Permitted Transferees to be
present in person or represented by proxy at all meetings (whether annual or special) of stockholders of the Company, so that all such shares of Common Stock shall be counted as present for determining the presence of a quorum at such meetings. 

SECTION 2.4.    Consent Rights. In addition to any vote or consent of the Board or the Stockholders required
by applicable Law, the Certificate of Incorporation or the By-Laws, and notwithstanding anything to the contrary in this Agreement (but subject to Section 2.6), for so long as Kate
Investor (together with its Permitted Transferees) beneficially owns at least five percent (5%) of the Outstanding Capital Shares, the Company shall not, and to the extent applicable, shall not permit any Subsidiary of the Company to, take any of
the following actions (or enter into any agreement or contract to take any of the following actions), without the prior written consent of Kate Investor: 

(a)    amend or otherwise modify any provision of the Certificate of Incorporation or the
By-Laws (whether by amendment, or through merger, recapitalization, consolidation or otherwise) in a manner that adversely and disproportionately affects Kate Investor or its Permitted Transferees; 

(b)    enter into any transaction or arrangement between the Company or any of its Subsidiaries, on the one hand, and any
Affiliate of the Company or any of its Subsidiaries (and such Affiliate is not otherwise a Subsidiary of the Company), on the other hand, other than any transaction or arrangement that is on terms that are not materially less favorable to the

  
 10 

 
Company or such Subsidiary than those that would have been obtained in a comparable transaction entered into with an unaffiliated third party that are reasonably determined to be on an
arms’-length basis; provided that this Section 2.4(b) shall not apply to (1) the entering into, maintaining or performance of instruments or agreements related to or in connection with an IPO that
are customary in form and substance with similar instruments or agreements entered into in connection with SEC-registered initial public offerings of U.S.-based subsidiaries by
non-U.S. parent companies, and that are either (A) continuations or extensions of, or immaterial modifications to, existing instruments or agreements in effect on the date of this Agreement or
(B) new instruments or agreements entered into on terms that are fair and reasonable to the Company and its Subsidiaries in all material respects, (2) the entering into, maintaining or performance of any customary transition
services agreement related to or in connection with an IPO as long as the charges for any service thereunder will not be any higher than a cost plus 5% basis or (3) the transactions set forth on Schedule 2.4; 

(c)    make any payments (including in respect of existing debt or equity (other than Common Stock dividends in which Kate
Investor and its Permitted Transferees participate on a pro rata basis)) to any Affiliate of the Company (other than the Company or any of its Subsidiaries), other than any payment that (x) is on terms that are not
materially less favorable to the Company or such Subsidiary than those that would have been obtained for a comparable payment to an unaffiliated third party that are reasonably determined to be on an arms’-length basis; provided that
this Section 2.4(c) shall not apply to (1) payments under any instruments or agreements related to or in connection with an IPO that are customary in form and substance with similar instruments or agreements
entered into in connection with SEC-registered initial public offerings of U.S.-based subsidiaries by non-U.S. parent companies, and that are either
(A) continuations or extensions of, or immaterial modifications to, existing instruments or agreements in effect on the date of this Agreement or (B) new instruments or agreements entered into on terms that are fair and
reasonable to the Company and its Subsidiaries in all material respects, (2) payments under any customary transition services agreement related to or in connection with an IPO as long as the charges for any service thereunder will not be
any higher than a cost plus 5% basis or (3) the payments set forth on Schedule 2.4; provided, further, that in no event shall consent from Kate Investor be required under both Section 2.4(b)
and this Section 2.4(c). 
 (d)    issue any new class of securities, recapitalize or effect
any similar event unless all holders of Common Stock are affected equally on a pro rata basis; 
 (e)    issue
any shares of Class B Common Stock or securities convertible into or exercisable or exchangeable for shares of Class B Common Stock other than to Kate Investor or its Permitted Transferees; 

(f)    enter into an agreement for or consummate a merger or other business combination in which any holders of Common
Stock Equivalents receive any consideration that is not shared equally and on a pro rata basis with all holders of Common Stock; or 

(g)    commence any plan of voluntary liquidation, dissolution or winding up of the Company or file any voluntary petition
for bankruptcy, receivership or any similar proceeding for the Company or any Significant Subsidiary (as defined in the Debt Financing Documents). 

  
 11 

 SECTION 2.5.    Financial Information. The Company shall
deliver or cause to be delivered the following information to Kate Investor for so long as it and its Permitted Transferees beneficially own in the aggregate at least five percent (5%) of the Outstanding Capital Shares: 

(a)    Quarterly Reports. As soon as available after the end of the first, second and third
quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, an unaudited consolidated balance sheet of the Company and its Subsidiaries as of the end of each such quarterly period,
and the related consolidated statements of operations, stockholders’ equity and cash flows of the Company and its Subsidiaries for such quarterly period and for the current fiscal year to date, prepared in accordance with GAAP consistently
applied (subject to normal year-end audit adjustments and the absence of notes thereto); 

(b)    Annual Reports. As soon as available after the end of each fiscal year of the Company, and in
any event within ninety (90) days thereafter, an audited consolidated balance sheet of the Company and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of operations, stockholders’ equity and cash
flows of the Company and its Subsidiaries for such fiscal year, prepared in accordance with GAAP consistently applied, and accompanied by the reports thereon of the Company’s independent auditors; 

(c)    Other Requested Information. With reasonable promptness upon the reasonable request of Kate
Investor, such other information and data (including such information and reports made available to any lender of the Company or any of its Subsidiaries under the Debt Financing Documents) with respect to the Company and each of its Subsidiaries as
may be necessary (i) for Kate Investor or its Permitted Transferees to monitor its investment in the Company or (ii) to enable Kate Investor or its Permitted Transferees to comply with their respective reporting, regulatory
or other legal requirements; provided, that notwithstanding the foregoing, the Company shall not be required to provide any such information if the Company reasonably determines in good faith, based on the advice of internal or outside
counsel, that (A) such information is competitively sensitive information relating to the Company’s or any Company Subsidiary’s business or (B) providing such information (1) would reasonably be expected
to result in a loss of an attorney-client privilege or a loss of attorney work product protection or (2) would violate any applicable Law; provided, further, that, with respect to clauses (A) and (B), the
Company uses reasonable efforts, and cooperates in good faith with Kate Investor, to develop and implement reasonable alternative arrangements to provide Kate Investor with the intended benefits of this
Section 2.5(c) to the fullest extent practicable under the circumstances. 

SECTION 2.6.    Termination of Rights Upon IPO. All rights and obligations of the Stockholders and the
Company under this Article II shall terminate automatically upon the consummation of an IPO. 

  
 12 

 ARTICLE III 

TRANSFERS 

SECTION 3.1.    Restrictions on Transfer. 

(a)    General. No Stockholder may Transfer any of its Equity Securities except in compliance with applicable
federal (including the Securities Act) and state securities Laws and all applicable provisions of this Agreement. Any Transfer or attempted Transfer of Equity Securities in violation of any provision of this Agreement shall be null and void
ab initio, and the Company shall not, and shall instruct its transfer agent and other third parties not to, record or recognize any such purported transaction on the share register or other books and records of the Company. The
approval of any Transfer in any one or more instances shall not limit or waive the requirement for such approval in any other or future instance. Notwithstanding anything to the contrary in this Agreement, neither Kate Investor nor any of its
Permitted Transferees may Transfer any Equity Securities to any Competitor (other than a Transfer (i) in a Tag-Along Transaction or (ii) in a Drag-Along Transaction). 

(b)    Lock-Up. Notwithstanding anything to the contrary in this Agreement,
prior to the fifth (5th) anniversary of the Closing Date, neither Kate Investor nor any of its Permitted Transferees may Transfer any Equity Securities to any Person (other than a Transfer (i) to a Permitted Transferee,
(ii) in a Tag-Along Transaction, (iii) in a Drag-Along Transaction or (iv) to the Company or any of its Subsidiaries (including by way of surrender, repurchase or
redemption) pursuant to this Agreement). 
 (c)    Conditions to Permitted Transfers. From and after the date of
this Agreement, it shall be a condition precedent to any Transfer to any Person of any Equity Securities otherwise permitted under this Agreement (including any Transfer to a Permitted Transferee) that the Transferee (i) if not already
party to this Agreement, become a party to this Agreement by executing and delivering a joinder agreement hereto, in form and substance reasonably acceptable to the Company, in which such Transferee agrees to be subject to all covenants and
agreements of the Stockholder Transferring such Equity Securities under this Agreement and (ii) execute, in its capacity as a Stockholder, all other agreements in effect immediately prior to the consummation of the Transfer binding on
the Company or Parent, on the one hand, and each Stockholder or its Permitted Transferees or Affiliates, in its capacity as a Stockholder, on the other hand. Such Transferee shall, upon satisfaction of such conditions to the reasonable satisfaction
of the Company, and its acquisition of Equity Securities, be a Stockholder for all purposes under this Agreement. 

(d)    Legends; Securities Law Compliance. In the event that the Equity Securities are represented by certificates,
each certificate representing the Equity Securities owned by any Stockholder shall bear the following legends: 

        (i)    THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED, SOLD, PLEDGED, 

  
 13 

 
HYPOTHECATED OR OTHERWISE DISPOSED OF UNLESS (X) (A) SUCH DISPOSITION IS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (B) THE HOLDER
HEREOF SHALL, IF REQUESTED BY THE COMPANY, HAVE DELIVERED TO THE COMPANY AN OPINION OF COUNSEL, WHICH OPINION AND COUNSEL SHALL BE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT SUCH DISPOSITION IS EXEMPT FROM THE PROVISIONS OF SECTION 5
OF SUCH ACT OR (C) A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION, REASONABLY SATISFACTORY TO COUNSEL FOR THE COMPANY, SHALL HAVE BEEN OBTAINED WITH RESPECT TO SUCH DISPOSITION AND
(Y) SUCH DISPOSITION IS PURSUANT TO REGISTRATION UNDER ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION THEREFROM. 

        (ii)    THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE
SUBJECT TO TRANSFER, VOTING AND OTHER RESTRICTIONS SET FORTH IN A STOCKHOLDERS AGREEMENT, DATED AS OF JULY 17, 2020 (AS IT MAY BE AMENDED), AMONG THE COMPANY AND THE OTHER PARTIES THERETO, COPIES OF WHICH ARE ON FILE WITH THE COMPANY. 

In addition, certificates representing Equity Securities shall bear any legends required by applicable state Law. The requirement that the legends required by
this Section 3.1(d) be placed upon certificates representing Equity Securities shall cease and terminate at such time as they are no longer required for purposes of applicable securities Law; provided that the
Company may condition replacement of a certificate for a certificate not bearing such legends upon the receipt of an opinion of securities counsel reasonably satisfactory to the Company. Prior to an IPO, neither Kate Investor nor any of its
Permitted Transferees shall Transfer Equity Securities if such Transfer would result in the Company becoming subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act (or other similar provision of non-U.S. Law) as determined by the Company in its sole and absolute discretion. 

(e)    Expiration Upon an IPO. The provisions of this Section 3.1 shall terminate upon
the consummation of an IPO. 
 SECTION 3.2.    Right of First Refusal. 

(a)    General. Subject to the terms and conditions of this Section 3.2, following the
fifth (5th) anniversary of the Closing Date, the Company and Parent shall have a right of first refusal if any other Stockholder (each, a “ROFR Initiator”) proposes to Transfer to any Person any Equity Securities owned by it, other
than (i) to Permitted Transferees, in the case of Kate Investor or its Permitted Transferees, or Affiliates, in the case of any other Stockholder, (ii) as a Tag-Along Participant
pursuant to Section 3.3 or as a Dragged Stockholder pursuant to Section 3.4, (iii) to the Company or any of its Subsidiaries or Parent or (iv) in connection with an IPO as part
of such registered offering (each such proposed Transfer, a “ROFR Proposed Transfer”). 

  
 14 

 (b)    ROFR Initiation Notice. Each time a ROFR Initiator
proposes to make a ROFR Proposed Transfer of any Equity Securities owned by it (the “Transfer Shares”), the ROFR Initiator shall give a written notice (the “ROFR Initiator Notice”) to the Company and Parent,
specifying the number of Transfer Shares and containing an irrevocable offer to Transfer the Transfer Shares to the Company or Parent (at the Company and Parent’s option) at the price, and upon the other material terms and conditions, specified
in the ROFR Initiator Notice (the “Transfer Price”). The Transfer Price shall be equal to the price offered (the “Purchase Offer”) to the ROFR Initiator by a bona fide third-party offeror (the “Third-Party
Offeror”), the identity of which shall be specified in the ROFR Initiator Notice. If the Purchase Offer is contained in a written proposal, a copy of such written proposal shall be provided with the ROFR Initiator Notice. The Company and
Parent shall treat as confidential the ROFR Initiator Notice, the information contained therein and any written proposal provided in connection therewith. 

(c)    Exercise of ROFR. Within thirty (30) Business Days after receipt of the ROFR Initiator Notice (the
“ROFR Exercise Period”), the Company or Parent may exercise the right of first refusal under Section 3.2(a) by giving a written notice to the ROFR Initiator (a “ROFR Notice”), which notice
shall specify that the Company or Parent, as applicable, wishes to purchase all (but not less than all) of the Transfer Shares for the Transfer Price. Any ROFR Notice shall upon delivery become binding on the Company or Parent, as applicable, and
shall become irrevocable without the necessity of any acceptance thereof by the ROFR Initiator. The Company or Parent’s, as applicable, failure to timely deliver a valid ROFR Notice shall be deemed an election by such party not to purchase the
Transfer Shares. 
 (d)    Closing of ROFR Purchase. The closing of any purchase of the Transfer Shares by the
Company or Parent, as applicable, pursuant to this Section 3.2 shall be subject to receipt of applicable regulatory approvals, if any. Such closing shall be held at a location to be designated by the Company or Parent, as
applicable, on a Business Day to be chosen by the Company or Parent, as applicable, which shall not be later than sixty (60) Business Days after the delivery of the ROFR Notice pursuant to Section 3.2(c) (or as
promptly as practicable thereafter if regulatory approvals are required and not obtained prior to such date). Upon the consummation of the purchase by the Company or Parent, as applicable, of the Transfer Shares pursuant to this
Section 3.2 and delivery by the ROFR Initiator of the duly endorsed certificate or certificates representing the Transfer Shares (which Transfer Shares shall be delivered free and clear of any liens or encumbrances other
than those existing under applicable securities Laws and pursuant to this Agreement and the Registration Rights Agreement), together with a stock power duly executed in blank, the Company or Parent, as applicable, shall remit directly to the ROFR
Initiator, by wire transfer of immediately available funds, the consideration for the Transfer Shares. 

(e)    Permitted Sale to Third Party Offeror. If, at the end of the ROFR Exercise Period, neither the Company nor
Parent has delivered to the ROFR Initiator an effective ROFR Notice, then the ROFR Initiator shall have sixty (60) Business Days after the expiration of the ROFR Exercise Period (or such longer period as may be required if regulatory approvals
are required and not obtained prior to such date) during which to Transfer all (but not less than all) of the Transfer Shares to the Third-Party Offeror, at a price not lower than the Transfer Price and on terms no more favorable to the Third-Party
Offeror in all material respects than those contained in the ROFR Initiator Notice (other than with respect to the addition of representations 

  
 15 

 
and warranties and corresponding indemnification protection). If, at the end of such sixty (60)-Business Day period (or such longer period as may be required if regulatory approvals are required
and not obtained prior to such date), the ROFR Initiator has not completed the Transfer of the Transfer Shares to the Third-Party Offeror, the ROFR Initiator shall no longer be permitted to Transfer the Transfer Shares to the Third-Party Offeror or
any other Person without again complying with the requirements of this Section 3.2; provided, however, that if the ROFR Initiator determines at any time within such sixty (60)-Business Day period that the
Transfer of the Transfer Shares to the Third-Party Offeror at a price not lower than the Transfer Price and on terms no more favorable to the Third-Party Offeror in all material respects than those contained in the ROFR Initiator Notice (other than
with respect to the addition of representations and warranties and corresponding indemnification protection) is impractical, the ROFR Initiator may terminate all attempts to Transfer the Transfer Shares and recommence the procedures described in
this Section 3.2 prior to the expiration of such sixty (60)-Business Day period by delivering a written notice thereof to the Company and Parent. 

(f)    Termination of ROFR. The rights set forth in this Section 3.2 shall terminate upon
the consummation of an IPO. 
 SECTION 3.3.    Tag-Along Right. 

(a)    General. In the event of a proposed Transfer of Equity Securities by Parent (the “Transferring
Stockholder”) to any Person (other than Transfers (i) to Affiliates, (ii) in connection with an IPO as a part of such registered offering or (iii) pursuant to a Drag-Along Transaction), each of Kate
Investor and its Permitted Transferees (each, a “Tag-Along Participant”) shall have the right to participate in such proposed Transfer in the manner set forth in this
Section 3.3 (a “Tag-Along Transaction”). 

(b)    Required Tag-Along Notice. Prior to any such Transfer described in
Section 3.3(a), the Transferring Stockholder shall deliver to the potential Tag-Along Participants and the Company written notice (the “Transfer Notice”), which
notice shall state (i) the name of the proposed Transferee, (ii) the number and form of Equity Securities proposed to be Transferred (the “Tag-Along Securities”)
(including a calculation of the number of shares of Common Stock underlying any Tag-Along Securities to the extent not shares of Common Stock), (iii) the proposed purchase price therefor, including
a description of any non-cash consideration, and (iv) a summary of the other material terms and conditions of the proposed Transfer, including the proposed Transfer date (which date may not be less
than thirty (30) days after delivery of the Transfer Notice). 
 (c)    Exercise of Tag-Along Right. The Tag-Along Participants may, subject to the limitations set forth in this Section 3.3(c), in the aggregate Transfer to the
proposed Transferee identified in the Transfer Notice up to a percentage (the “Tag-Along Percentage”) of the Tag-Along Participants’ aggregate
beneficial ownership of Equity Securities equal to the percentage of the Equity Securities beneficially owned by the Transferring Stockholder represented by the number of Tag-Along Securities set forth in the
Transfer Notice by giving written notice (the “Tag-Along Acceptance Notice”) to the Transferring Stockholder and the Company (who shall forward such notice to the other Tag-Along Participants within two (2) Business Days of the Company’s receipt of such notice) within fifteen (15) Business Days after 

  
 16 

 
receipt of the Transfer Notice, stating that such Tag-Along Participant elects to exercise its tag-along right
under this Section 3.3 and stating the maximum number of Equity Securities sought to be Transferred by such Tag-Along Participant; provided that in the event the Tag-Along Participants in the aggregate seek to sell more Equity Securities than are permitted by this Section 3.3(c) then the amount to be sold shall be allocated among the Tag-Along Participants on a pro rata basis based upon the number of Equity Securities beneficially owned by each or in such other manner as may be mutually agreed by the participating Tag-Along Participants. Each Tag-Along Participant shall be deemed to have waived its tag-along right hereunder if it fails to give the
Tag-Along Acceptance Notice within the prescribed time period. The proposed Transferee of Tag-Along Securities will not be obligated to purchase a number of Equity
Securities exceeding that set forth in the Transfer Notice, and in the event such Transferee elects to purchase less than all of the additional Equity Securities sought to be Transferred by the Tag-Along
Participants, the number of Equity Securities to be Transferred by the Transferring Stockholder shall be reduced to the Transferring Stockholder’s Pro Rata Portion and the number of Equity Securities to be Transferred by the Tag-Along Participants in the aggregate shall be reduced to the Tag-Along Participants’ aggregate Pro Rata Portion. 

(d)    Delivery of Securities. A Tag-Along Participant, in exercising its tag-along right hereunder, shall deliver to the Transferring Stockholder at the closing of the Transfer of the Transferring Stockholder’s Tag-Along Securities to the
Transferee certificates representing the Tag-Along Securities to be Transferred by such holder (free and clear of any liens or encumbrances other than those existing under applicable securities Laws and
pursuant to this Agreement and the Registration Rights Agreement), duly endorsed for transfer or accompanied by stock powers duly executed, in either case executed in blank or in favor of the applicable purchaser against payment of the aggregate
purchase price therefor by wire transfer of immediately available funds. The shares of Class B Common Stock held by Kate Investor or its Permitted Transferees subject to the Tag-Along Transaction shall
convert into Class A Common Stock on a 1:1 basis immediately prior to such Tag-Along Transaction. 

(e)    Consideration; Representations; No Liability. In connection with any
Tag-Along Transaction, all Tag-Along Participants who participate in such transaction shall be obligated, if applicable, to vote (or consent in writing, as the case may
be) all Equity Securities with voting rights held by them in favor of any Tag-Along Transaction and shall execute all documents, including a sale or purchase agreement, reasonably requested by the Company or
the Transferring Stockholder containing the terms and conditions of the Tag-Along Transaction; provided that each Tag-Along Participant shall agree to make
customary representations, and shall agree to customary covenants, indemnities and agreements so long as they are made severally and not jointly; provided, further, that (i) any general indemnity given by the Transferring
Stockholder to the Transferee in connection with such sale that is applicable to liabilities not specific to the Transferring Stockholder, shall be apportioned among the Tag-Along Participants and the
Transferring Stockholder on a pro rata basis, based on the consideration received by each such Stockholder in respect of its Equity Securities to be Transferred and shall not exceed such Stockholder’s net proceeds from the sale,
(ii) any representation relating specifically to a Stockholder or its ownership of the Equity Securities to be Transferred shall be made only by such Stockholder and (iii) in no event shall any
Tag-Along Participant be obligated to agree to any non-competition covenant, employee non-solicit covenant or other similar
agreement restricting the business operations of such Tag-Along 

  
 17 

 
Participant or its Affiliates as a condition to participating in such Tag-Along Transaction. Each Tag-Along
Participant and the Transferring Stockholder shall receive consideration in the same form and per share amount (on a per Common Stock equivalent basis) after deduction of such Stockholder’s proportionate share of the related expenses (to the
extent such expenses are not borne by the Company or the Transferee); provided, however, that if the Transferring Stockholder is given an option as to the form and amount of consideration to be received, all Tag-Along Participants will be given the same option. The proposed closing of the Tag-Along Transaction may be extended beyond the date described in the Transfer Notice to the
extent necessary to obtain required governmental approvals and other required third-party approvals and the Company and the Transferring Stockholders shall use their respective reasonable best efforts to obtain such approvals. The Transferring
Stockholder shall, in its sole discretion, decide whether or not to pursue, consummate, postpone or abandon any proposed Tag-Along Transaction subject to this Section 3.3 and the
terms and conditions thereof. No Stockholder or Affiliate of a Stockholder shall have any liability to any other Stockholder or the Company arising from, relating to or in connection with the pursuit, consummation, postponement, abandonment or terms
and conditions of any proposed Tag-Along Transaction subject to this Section 3.3 except to the extent such Stockholder shall have failed to comply with the provisions of this
Section 3.3. In addition, no Tag-Along Participant participating in a Tag-Along Transaction shall exercise any rights of appraisal or
dissenters rights that such Tag-Along Participant may have (whether under applicable Law or otherwise) in connection with any proposed Tag-Along Transaction. 

(f)    Fees and Expenses. The fees and expenses incurred in connection with a
Tag-Along Transaction and for the benefit of all Stockholders (it being understood that costs incurred by or on behalf of a Stockholder for his, her or its sole benefit will not be considered to be for the
benefit of all Stockholders), to the extent not paid or reimbursed by the Company or the Transferee, shall be shared by all Tag-Along Participants and the Transferring Stockholder on a pro rata basis, based on
the consideration received by each such Stockholder in respect of its Equity Securities to be Transferred; provided that no such Tag-Along Participant shall be obligated to make any out-of-pocket expenditure in respect of such fees or expenses prior to the consummation of the such Tag-Along Transaction (excluding de
minimis expenditures). 
 (g)    Satisfaction of Tag-Along Obligations After
Sale. Notwithstanding the foregoing requirements of this Section 3.3, the Transferring Stockholder may satisfy its obligations under this Section 3.3 by proceeding with the Transfer of the Tag-Along Securities and, after the closing of such Transfer, acquiring (or causing the proposed Transferee to acquire) the Equity Securities that each electing Tag-Along
Participant was otherwise entitled to sell under this Section 3.3 on the same terms and conditions as the Transfer by the Transferring Stockholder of such Tag-Along Securities (for
the avoidance of doubt, including with respect to indemnification, but for the benefit of the Transferring Stockholder, such as to put each of the Transferring Stockholder and Tag-Along Participants in
substantially the same position as if the sale had been made by the Tag-Along Participants directly to the Transferee). 

(h)    Termination of Tag-Along Right. The rights set forth in this
Section 3.3 shall terminate upon the consummation of an IPO. 

  
 18 

 SECTION 3.4.    Drag-Along Right. 

(a)    General. If Parent (the “Exiting Stockholder”) proposes to Transfer all of its Outstanding
Capital Shares to any Person in a transaction or series of transactions (other than Transfers (i) to Affiliates, (ii) in connection with an IPO as a part of such registered offering or (iii) pursuant to a Tag-Along Transaction), where such Outstanding Capital Shares held by the Exiting Stockholder constitutes more than fifty percent (50%) of the total number of Outstanding Capital Shares, then each other Stockholder
(each, a “Dragged Stockholder”) shall be required to Transfer all of its Equity Securities in accordance with this Section 3.4 (a “Drag-Along Transaction”); provided that the
proceeds and other rights received in respect of such Drag-Along Transaction shall be shared by all Dragged Stockholders and the Exiting Stockholder on a pro rata basis, based on the number of Outstanding Capital Shares Transferred by each
Stockholder in such Drag-Along Transaction. 
 (b)    Terms of Drag-Along Transaction. The terms and conditions
of such Drag-Along Transaction applicable to the Dragged Stockholders shall be the same as those upon which the Exiting Stockholder sells its Equity Securities in the Drag-Along Transaction. In connection with the Drag-Along Transaction, each
Dragged Stockholder shall agree to make or agree to the same customary representations, covenants, indemnities and agreements as the Exiting Stockholder, so long as they are made severally and not jointly and the liabilities thereunder are borne on
a pro rata basis, based on the consideration to be received by each Stockholder in such Drag-Along Transaction; provided, however, that (i) any general indemnity given by the Exiting Stockholder to the purchaser in
connection with such sale that is applicable to liabilities not specific to the Exiting Stockholder shall be apportioned among the Dragged Stockholders and the Exiting Stockholder according to the consideration received by each Dragged Stockholder
and the Exiting Stockholder in such Drag-Along Transaction and shall not (together with any other indemnities to be provided by such Stockholder in such Drag-Along Transaction, including those described in clause (ii) below) exceed such
Stockholder’s net proceeds from the sale, (ii) any representation relating specifically to a Dragged Stockholder shall be made only by that Dragged Stockholder, and any indemnity given with respect to such representation shall be
given only by such Dragged Stockholder and (iii) in no event shall any Dragged Stockholder be obligated to agree to any non-competition covenant, employee
non-solicit covenant or other similar agreement restricting the business operations of the Dragged Stockholder or its Affiliates. 

(c)    Approval of Drag-Along Transaction. In connection with any Drag-Along Transaction proposed to be completed
in accordance with this Agreement, each Dragged Stockholder shall be required to vote, if such a vote is required by this Agreement or otherwise, all of its Equity Securities entitled to vote on such Drag-Along Transaction in favor of such
Drag-Along Transaction at any meeting of the Stockholders called to vote on or approve such Drag-Along Transaction or to consent in writing to such Drag-Along Transaction, to use its reasonable best efforts to cause any Directors designated by such
Dragged Stockholder to vote in favor of such Drag-Along Transaction at any meeting of the Board called to vote on or approve such Drag-Along Transaction or to consent in writing to such Drag-Along Transaction and raise no objection thereto, and the
Dragged Stockholders and the Company shall take all other actions necessary or reasonably required to cause, and shall not interfere with, the consummation of such Drag-Along Transaction on the terms and conditions proposed by the Exiting
Stockholder, 

  
 19 

 
including executing, acknowledging and delivering customary consents, assignments, waivers and other documents or instruments, furnishing information and copies of documents, and filing
applications, reports, returns and other documents or instruments with governmental authorities. Without limiting the foregoing, if the proposed Drag-Along Transaction is structured as a merger, consolidation or similar transaction, then each
Stockholder shall vote or cause to be voted all Equity Securities that such Stockholder holds or with respect to which such Stockholder has the power to direct the voting and which are entitled to vote on such transaction in favor of such
transaction and shall waive any dissenter’s rights, appraisal rights or similar rights which such Stockholder may have in connection therewith. 

(d)    Fees and Expenses. The fees and expenses, other than those payable to any Stockholder or any of their
respective Affiliates, incurred in connection with a Drag-Along Transaction under this Section 3.4 and for the benefit of all Stockholders (it being understood that costs incurred by or on behalf of a Stockholder for his,
her or its sole benefit will not be considered to be for the benefit of all Stockholders), to the extent not paid or reimbursed by the Company or acquiring Person, shall be shared by all the Stockholders on a pro rata basis, based on the
consideration received by each Stockholder in such Drag-Along Transaction; provided, however, that no Stockholder shall be obligated to make any
out-of-pocket expenditure prior to the consummation of the Drag-Along Transaction consummated pursuant to this Section 3.4(d) (excluding de
minimis expenditures). 
 (e)    Required Drag-Along Notice. The Exiting Stockholder shall provide written notice
(the “Drag-Along Notice”) to each Dragged Stockholder of any proposed Drag-Along Transaction as soon as reasonably practicable following its exercise of the rights provided in Section 3.4(a). The Drag-Along
Notice will include a summary of the material terms and conditions of the Drag-Along Transaction, including (i) the name and address of the proposed Transferee, (ii) the proposed amount and form of consideration and
(iii) the proposed Transfer date, if known. Notwithstanding anything to the contrary in this Agreement, after the Drag-Along Notice has been provided by the Exiting Stockholder to the Dragged Stockholders pursuant to this
Section 3.4(e) with respect to any proposed Drag-Along Transaction, no Dragged Stockholder may Transfer any of its Equity Securities to any Person (other than a Permitted Transferee), until the earlier of
(x) the delivery of a withdrawal notice by the Exiting Stockholder pursuant to Section 3.4(h) and (y) the expiration of a one-hundred and eighty (180)-day period after the delivery of the Drag-Along Notice by the Exiting Stockholder, other than as part of such Drag-Along Transaction and in accordance with this Section 3.4. 

(f)    Form of Consideration. If any holders of Equity Securities of any class are given an option as to the form
and amount of consideration to be received, all holders of Equity Securities will be given the same option on a per Common Stock equivalent basis. 

(g)    Consummation of Drag-Along Transaction. At least five (5) Business Days prior to the consummation of
the Drag-Along Transaction, each Dragged Stockholder shall deliver to the Company to hold in escrow pending transfer of the consideration therefor, the duly endorsed certificate or certificates representing such Equity Securities held by such
Dragged Stockholder to be sold, and a stock power duly executed in blank and limited power of attorney authorizing the Company to execute all transaction agreements contemplated by the terms of this Section 3.4. In the
event that a Dragged Stockholder should fail to deliver such certificates, 

  
 20 

 
letters and documentation, the Company shall cause the books and records of the Company to show that such Equity Securities are bound by the provisions of this
Section 3.4 and that such securities may be Transferred only to the purchaser in such Drag-Along Transaction in accordance with the terms of this Section 3.4. The shares of Class B Common
Stock held by Kate Investor or its Permitted Transferees subject to the Drag-Along Transaction shall convert into Class A Common Stock on a 1:1 basis immediately prior to such Drag-Along Transaction. Upon the consummation of the Drag-Along
Transaction, the acquiring Person shall remit directly to the Dragged Stockholder and the Exiting Stockholder, by wire transfer if available and if requested by the Dragged Stockholder or the Exiting Stockholder, as applicable, the consideration for
the securities sold pursuant thereto. 
 (h)    No Liability. The Exiting Stockholder shall, in its sole
discretion, decide whether or not to pursue, consummate, postpone or abandon any proposed Transfer subject to this Section 3.4 and the terms and conditions hereof. Promptly following a definitive decision not to pursue or
consummate a Drag-Along Transaction for which the Exiting Stockholder has previously sent a Drag-Along Notice, the Exiting Stockholder shall notify the other Stockholders of such decision and the transfer restriction set forth in the last sentence
of Section 3.4(e) shall expire upon the date of such withdrawal notice. No Stockholder or Affiliate of a Stockholder shall have any liability to any other Stockholder or the Company arising from, relating to or in
connection with the pursuit, consummation, postponement, abandonment or terms and conditions of any proposed Transfer subject to this Section 3.4, except to the extent such Stockholder shall have failed to comply with the
provisions of this Section 3.4. 
 (i)    Termination of Drag-Along Right. The rights
set forth in this Section 3.4 shall terminate upon the consummation of an IPO. 

SECTION 3.5.    IPO Cooperation. Kate Investor acknowledges that the Company entered into the Investment
Agreement, and the Company and Parent have entered this Agreement and the transactions contemplated hereby and thereby in anticipation of pursuing an IPO, the structure of which is yet to be determined. Kate Investor shall use its commercially
reasonable efforts to cooperate with the Company in pursuing an IPO, shall provide any information reasonably requested by the Company in connection with any such transaction, and shall not take steps that would reasonably be expected to interfere
with any such transaction. In the event that an IPO involving the Company and/or one or more of its Subsidiaries is effected other than through a listing of the Company, all of the Outstanding Capital Shares beneficially owned by Kate Investor and
its Permitted Transferees shall be, and Kate Investor hereby consents and agrees to such Outstanding Capital Shares being, converted or rolled over into, or transferred or exchanged for, shares of the registrant in the IPO, such that, following such
conversion, rollover, transfer or exchange, Kate Investor and its Permitted Transferees will have the same beneficial ownership and other rights in the IPO registrant as Kate Investor and its Permitted Transferees had in the Company and would have
had in the resulting public company as if the Company were the issuer in such transaction (including, if the resulting public company does not own all of the businesses and assets of the Company and its Subsidiaries, Kate Investor and its Permitted
Transferees retaining their respective economic interests in any such excluded businesses or assets). Kate Investor further acknowledges that between the date of this Agreement the consummation of an IPO, the Company and its Subsidiaries intend to
incur third party indebtedness, the proceeds of which (in whole or in part) will be used to repay in full the term loan facility date November 7, 2019 between the Company, Prudential plc and Standard Chartered Bank, New York Branch. 

  
 21 

 ARTICLE IV 

EQUITY PURCHASE RIGHTS 

SECTION 4.1.    Equity Purchase Rights. 

(a)    General. For so long as Kate Investor (together with its Permitted Transferees) (collectively, the
“Preemptive Rights Recipients”) beneficially owns in the aggregate a number of Outstanding Capital Shares representing at least fifty percent (50%) of the number of Outstanding Capital Shares that it beneficially owned as of the
Closing, the Preemptive Rights Recipients shall have the right to participate in any issuance of New Securities by the Company or any of its Subsidiaries, on the terms and subject to the conditions set forth in this
Section 4.1. For the avoidance of doubt, the equity purchase right provided in this Section 4.1 shall apply at the time of issuance of any right, warrant or option or convertible or exchangeable
security, and not to the conversion, exchange or exercise thereof. 
 (b)    Notice of Issuance and Exercise. The
Company shall give the Preemptive Rights Recipients written notice at least fifteen (15) Business Days prior to the effective date of any issuance of New Securities described in Section 4.1(a) (an “Issuance
Notice”), describing the New Securities proposed to be issued, the proposed cash price per share, including a description of any non-cash consideration, and a summary of the other material terms and
conditions proposed for such issuance. Subject to the succeeding sentence, the Preemptive Rights Recipients shall have ten (10) Business Days after any Issuance Notice is delivered to notify the Company in writing that they will purchase their
Pro Rata Portion (or any lesser portion thereof that the Preemptive Rights Recipients elect), at the cash price (provided that, in the event that any portion of the purchase price per share to be paid by the proposed purchaser is to be paid
in non-cash consideration, the value of any such non-cash consideration per share shall be the Fair Market Value) and on the terms specified in such Issuance Notice. If
the Preemptive Rights Recipients in the aggregate elect to purchase more than the Pro Rata Portion, then the aggregate amount of New Securities to be purchased by the Preemptive Rights Recipients shall be equal to such Pro Rata Portion, and such
amount of New Securities shall be allocated among the Preemptive Rights Recipients electing to purchase such New Securities on a pro rata basis in accordance with their respective beneficial ownership of Outstanding Capital Shares or in such manner
as they may mutually agree. A Preemptive Rights Recipient’s failure to give written notice prior to the expiration of the ten (10) Business Day period above shall be deemed an election not to purchase any New Securities. If the Preemptive
Rights Recipients have delivered written notices covering in the aggregate less than all of the New Securities proposed to be issued under the Issuance Notice, then the Company or the applicable Subsidiary of the Company may issue, or permit to be
issued, any New Securities that such Preemptive Rights Recipient was offered to purchase under this Section 4.1 but did not elect to purchase, at a price no less than and on terms no more favorable as specified in the
Issuance Notice. 

  
 22 

 (c)    Closing of Issuance. The closing of any purchase by any
Preemptive Rights Recipient shall be consummated concurrently with the consummation of the issuance described in the applicable Issuance Notice; provided, however, that the closing of any purchase by any Preemptive Rights Recipient may
be extended beyond the closing of any issuance described in the applicable Issuance Notice to the extent necessary to obtain required governmental approvals and other required approvals, and the Company and the Stockholders shall use reasonable best
efforts to obtain such approvals; provided, further, that nothing herein shall preclude New Securities from being issued in advance of the Company or the applicable Subsidiary of the Company satisfying its obligations to the Preemptive
Rights Recipients under this Section 4.1 if the Board reasonably determines that it is in the best interests of the Company or such Subsidiary to do so, provided that any such outstanding obligations are satisfied as soon
as reasonably practicable. Upon the issuance of any New Securities in accordance with this Section 4.1, the Company or the applicable Subsidiary of the Company shall deliver the New Securities in certificated form (if the
Equity Securities are certificated), and the applicable Preemptive Rights Recipient shall deliver to the Company or the applicable Subsidiary of the Company the purchase price for the New Securities purchased by it by wire transfer of immediately
available funds. The Company and the Preemptive Rights Recipients shall enter into such additional agreements as may be necessary or appropriate for the issuance of the New Securities. 

SECTION 4.2.    Termination of Equity Purchase Rights. The rights set forth in
Section 4.1 shall terminate upon the consummation of an IPO. 
 ARTICLE V 

MISCELLANEOUS 

SECTION 5.1.    Certificate of Incorporation and By-Laws. The rights
and obligations of the Stockholders with respect to the Company shall be determined pursuant to the DGCL, the Certificate of Incorporation, the By-Laws and this Agreement. To the extent that the rights or
obligations of a Stockholder are different by reason of any provision of this Agreement than they would be in the absence of such provision, this Agreement, to the extent permitted by the DGCL, shall control. 

SECTION 5.2.    Termination. This Agreement shall be effective at the Closing and shall continue until
terminated by the mutual written consent of the Company and each of the Stockholders; provided that, to the extent any members of management of the Company are Stockholders, the consent of such members of management shall not be required for
termination. The rights and obligations of a Stockholder under this Agreement shall automatically terminate at such time as such Stockholder no longer beneficially owns any Equity Securities; provided that nothing herein shall relieve any
party from any liability for the breach of any of the agreements set forth in this Agreement. Notwithstanding the foregoing, the obligations of a Stockholder under Section 5.3 shall survive for a period of two
(2) years from the earlier to occur of (x) the date on which such Stockholder no longer beneficially owns any Equity Securities and (y) termination of this Agreement. 

SECTION 5.3.    Confidentiality. Each Stockholder agrees to, and shall cause its Representatives to, keep
confidential and not divulge any Information, and to use, and cause its Representatives to use, such Information only in connection with the operation of the Company 

  
 23 

 
and its Subsidiaries; provided that nothing herein shall prevent any Stockholder from disclosing such Information (i) upon the order of any court or administrative agency,
(ii) upon the request or demand of any regulatory agency or authority having jurisdiction over such Stockholder, (iii) to the extent required by Law or legal process or required or requested pursuant to subpoena,
interrogatories or other discovery requests, (iv) to the extent required to comply with its reporting, regulatory or other legal requirements, (v) to other Stockholders, (vi) to such Stockholder’s Representatives
that in the reasonable judgment of such party need to know such Information or (vii) to any bona fide proposed Transferee to whom such proposed Transfer would be permitted in accordance with Section 3.1 or
Section 3.2(e) in connection with a proposed Transfer of Equity Securities from such Stockholder, so long as such Transferee agrees to be bound by the provisions of this Section 5.3 as if a
Stockholder; provided further that, in the case of clause (i), (ii) or (iii), such party shall notify the Company of the proposed disclosure as far in advance of such disclosure as practicable and use
reasonable best efforts to ensure that any Information so disclosed is accorded confidential treatment, when and if available. Each Stockholder acknowledges that in its receipt of Information, it may have access to material, non-public information, and it is aware that state and federal Laws, including United States and foreign securities Laws, impose restrictions on the dissemination of such Information and trading in securities when
in possession of such Information or from communicating such Information to any other Person under circumstances in which it is reasonably foreseeable that such Person is likely to trade such securities. In addition, the parties acknowledge that
Prudential plc is subject to applicable Law relating to the use and dissemination of inside information (including, as at the date of this Agreement, the EU’s Market Abuse Regulation (Regulation 596/2014)) and that in particular, financial
information of the Company relevant to Prudential plc’s year end and interim results could constitute inside information and, in any event, must be treated with utmost confidentiality prior to Prudential plc announcing such results. 

SECTION 5.4.    Amendments. Except as otherwise provided herein, no modification or amendment of any provision
of this Agreement shall be effective without the consent of the Board; provided that this Agreement may not be amended in any manner adversely affecting the rights or obligations of any Stockholder or class of Stockholders, which does not, by
its terms, adversely affect the rights or obligations of all similarly situated Stockholders or classes of Stockholders in a substantially similar manner, without the consent of such Stockholder or a majority-in-interest of such class of Stockholders. Notwithstanding the foregoing, for the avoidance of doubt, no consent of any Stockholder shall be required for the Company to update Schedule 1.1 as
provided in this Agreement. 
 SECTION 5.5.    Successors, Assigns and Transferees. This Agreement shall
bind and inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns. Stockholders may assign their respective rights and obligations hereunder to any Transferees only to the extent
permitted herein. 
 SECTION 5.6.    Notices. All notices, requests, consents, claims, demands and other
communications under this Agreement shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by electronic mail with receipt confirmed or
by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following 

  
 24 

 
addresses, or at such other address for a party as shall be specified in a notice given in accordance with this Section 5.6: 

(a)     if to the Company, to: 

Jackson Financial Inc. 

1 Corporate Way 

Lansing, MI 48951 

USA 

Attention:        Thomas Hyatte 

E-mail:             
thomas.hyatte@jackson.com 
 with a copy (which shall not constitute notice) to: 

Debevoise & Plimpton LLP 

919 Third Avenue 

New York, New York 10022 

USA 

Attention:        Nicholas F. Potter 

                     
   Andrew L. Bab 

Email:             nfpotter@debevoise.com 

                     
   albab@debevoise.com 
 (b)     if to Parent, to: 

Prudential (US Holdco 1) Limited 

1 Angel Court 
 London EC2R 7AG

 UK 

Attention:        Corporate Secretary, PUSH 

Email:              Secretariat@prudentialplc.com 

with a copy (which shall not constitute notice) to: 

Debevoise & Plimpton LLP 

919 Third Avenue 
 New York, New
York 10022 
 USA 

Attention:        Nicholas F. Potter 

                       
 Andrew L. Bab 
 Email:             nfpotter@debevoise.com 

                     
   albab@debevoise.com 

  
 25 

 (c)     if to Kate Investor, to: 

Athene Life Re Ltd. 

Chesney House 

96 Pitts Bay Road 

Pembroke HM08 

Bermuda 

Attention:        Natasha Scotland Courcy 

E-mail:            ncourcy@athene.bm 

with a copy (which shall not constitute notice) to: 

Sidley Austin LLP 
 One South
Dearborn 
 Chicago, Illinois 60603 

USA 

Attention:        Perry J. Shwachman 

                     
   Jeremy C. Watson 

E-mail:            
pshwachman@sidley.com 

                     
   jcwatson@sidley.com 
 (d)     if to any other Stockholder, to the address of such other
Stockholder as shown in the stock record book of the Company. 
 SECTION 5.7.    Further Assurances. At any
time or from time to time after the date hereof, the parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other
party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated hereby in accordance with their terms and to otherwise carry out the intent of the parties hereunder. 

SECTION 5.8.    Entire Agreement; Third Party Beneficiaries. Except as otherwise expressly set forth herein
(or in the Investment Agreement or any other Transaction Agreement), this Agreement, together with the Investment Agreement and the other Transaction Agreements, embody the complete agreement and understanding among the parties hereto with respect
to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or among the parties, written or oral, that may have related to the subject matter hereof in any way. This Agreement is not intended
to confer in or on behalf of any Person not a party to this Agreement (and their successors and assigns) any rights, benefits, causes of action or remedies with respect to the subject matter or any provision thereof. 

SECTION 5.9.    Restrictions on Other Agreements. Following the date hereof, no Stockholder shall enter into
or agree to be bound by any stockholder agreements or arrangements of any kind with any Person with respect to any Equity Securities (other than the Transaction Agreements or any agreement with Prudential plc or its Subsidiaries and Affiliates), to
the extent that such agreement or arrangement would conflict with or violate any provision or term of this Agreement or otherwise be intended to circumvent the provisions set forth herein, except pursuant to the agreements specifically contemplated
by the Investment Agreement and the Registration Rights Agreement. 

  
 26 

 SECTION 5.10.    Delays or Omissions. It is agreed that no
delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, shall impair any such right, power or remedy, nor shall it be construed to be a waiver
of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on
the part of any party hereto of any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this Agreement, by Law, or otherwise afforded to any party, shall be cumulative and not alternative.

SECTION 5.11.    Governing Law; Submission to Jurisdiction; Waiver of Jury Trial. 

(a)    This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of
Delaware, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. In addition,
each of the parties (i) submits to the personal jurisdiction of the Delaware Court of Chancery in and for New Castle County, or in the event (but only in the event) that such Delaware Court of Chancery does not have subject matter
jurisdiction over such dispute, the United States District Court for the District of Delaware, or in the event (but only in the event) that such United States District Court also does not have jurisdiction over such dispute, any Delaware State court
sitting in New Castle County, in the event any dispute (whether in contract, tort or otherwise) arises out of this Agreement or the transactions contemplated hereby, (ii) agrees that it shall not attempt to deny or defeat such personal
jurisdiction by motion or other request for leave from any such court, and (iii) agrees that it shall not bring any claim, action or proceeding relating to this Agreement or the transactions contemplated hereby in any court other than
the Delaware Court of Chancery in and for New Castle County, or in the event (but only in the event) that such Delaware Court of Chancery does not have subject matter jurisdiction over such claim, action or proceeding, the United States District
Court for the District of Delaware, or in the event (but only in the event) that such United States District Court also does not have jurisdiction over such claim, action or proceeding, any Delaware State court sitting in New Castle County. Each
party agrees that service of process upon such party in any such claim, action or proceeding shall be effective if notice is given in accordance with the provisions of this Agreement. 

(b)    Each party hereby waives, to the fullest extent permitted by applicable Law, any right it may have to a trial by
jury in respect of any suit, action or other proceeding arising out of this Agreement or any transaction contemplated hereby. Each party (i) certifies and acknowledges that no Representative, agent or attorney of any other party has
represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, and (ii) acknowledges that it understands and has considered the implications of this waiver and
makes this waiver voluntarily, and that it and the other parties have been induced to enter into the Agreement by, among other things, the mutual waivers and certifications in this Section 5.11(b). 

  
 27 

 SECTION 5.12.    Specific Performance. The parties hereto
agree and acknowledge that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and it is therefore agreed that in addition to and without limiting any other remedy or right it may have, each non-breaching party may in its sole discretion apply to any court of Law or equity of competent jurisdiction for, and have the right to, specific performance and/or injunctive relief (without posting a bond or other
security) in order to prevent any violation of the provisions of this Agreement and enforce specifically the terms and provisions hereof, and if any action should be brought in equity to enforce any of the provisions of this Agreement none of the
parties hereto shall raise the defense that there is an adequate remedy at Law. 

SECTION 5.13.    Severability. If any term, provision, covenant or restriction of this Agreement is held by a
court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected,
impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party hereto. Upon such a determination, the parties shall negotiate in good faith to
modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent
possible. 
 SECTION 5.14.    Titles and Subtitles. The titles of the sections and subsections of this
Agreement are for convenience of reference only and will not affect the meaning or interpretation of this Agreement. 

SECTION 5.15.    No Recourse. Notwithstanding anything that may be expressed or implied in this Agreement, the
Company and each Stockholder covenant, agree and acknowledge that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee,
general or limited partner or member of any Stockholder or of any Affiliate or assignee thereof (other than any such Person serving as a Director and then solely to the extent in his or her capacity as such), whether by the enforcement of any
assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable Law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be
incurred by any current or future officer, agent or employee of any Stockholder or any current or future member of any Stockholder or any current or future director, officer, employee, partner or member of any Stockholder or of any Affiliate or
assignee thereof (other than any such Person serving as a Director and then solely to the extent in his or her capacity as such) for any obligation of any Stockholder under this Agreement or under any documents or instruments delivered in connection
with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation. 

SECTION 5.16.    Counterparts; Facsimile Signatures. This Agreement may be executed in counterparts, each of
which shall constitute one and the same instrument. Signatures provided by facsimile or electronic transmission in “pdf” or equivalent format will be deemed to be original signatures. 

  
 28 

 ARTICLE VI 

REPRESENTATIONS AND WARRANTIES 

SECTION 6.1.    Representations and Warranties of the Stockholders. Each Stockholder, severally and not
jointly, represents and warrants, solely with respect to itself, to each other and to the Company, as of the date such Stockholders becomes a party to this Agreement, as follows: 

(a)    Organization; Authority. If the Stockholder is a corporation, then it is duly incorporated, validly existing
and in good standing under the Laws of its jurisdiction of incorporation. If the Stockholder is a partnership, trust or limited liability company, then it is duly formed, validly existing and in good standing (to the extent applicable) under the
Laws of its jurisdiction of formation. Such Stockholder has all requisite power and authority to enter into this Agreement and to perform its obligations hereunder, and to consummate the transactions contemplated hereby. 

(b)    Due Authorization; Binding Agreement. This Agreement has been duly authorized, executed and delivered by
such Stockholder and constitutes a valid and binding obligation of such Stockholder enforceable against such Stockholder in accordance with its terms, except to the extent that the enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar Laws affecting the enforcement of creditors’ rights generally and general equitable principles, regardless of whether such enforceability is considered in a proceeding at law or in equity. If
such Stockholder is a trust, no consent of any beneficiary is required for the foregoing. 
 (c)    Non-Contravention. The Stockholder is not a party to any agreement which is inconsistent with its obligations hereunder or the rights of any party hereunder or otherwise conflicts with the provisions hereof. The
execution and delivery of this Agreement by such Stockholder, the performance of its obligations hereunder, and the consummation of the transactions contemplated hereby, will not violate, conflict with or result in a breach, or constitute a default
(with or without notice or lapse of time or both) under any provision of its charter, bylaws or other similar organizational documents or any agreement or other instrument to which it is a party. 

(d)    Consents and Approvals. Other than pursuant to this Agreement, no consent, waiver, approval or authorization
of, or filing, registration or qualification with, or notice to, any governmental unit or any other Person is required to be made, obtained or given by the Stockholder in connection with the execution, delivery and performance of this Agreement.

 (e)    Investment Intent. At such time at which the Stockholder acquired the Equity Securities,
(i) it acquired such Equity Securities for its own account with the intention of holding such securities for purposes of investment and (ii) it had no intention of selling such securities in a public distribution in violation
of the federal securities Laws or any applicable state securities Laws. 

  
 29 

 (f)    Securities Law Matters. The Stockholder is an
“accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

(g)    Restriction on Resale. The Stockholder understands and acknowledges that its Equity Securities have not been
registered for sale under any federal or state securities Law and must be held indefinitely unless subsequently registered or an exemption from such registration is available. 

(h)    Due Diligence. The Stockholder (i) has performed its own due diligence and business
investigations with respect to the Company, (ii) is fully familiar with the nature of the investment in the Company, the speculative and financial risks thereby assumed, and the uncertainty with respect to the timing and amounts of
distributions, if any, to be made by the Company and (iii) has had the opportunity to ask questions and receive answers concerning the terms and conditions of the offering of such Equity Securities and had access to such other
information concerning the Company as it requested. 
 [Remainder of page intentionally left blank] 

  
 30 

 IN WITNESS WHEREOF, the parties hereto have executed this Stockholders Agreement as of the
date first set forth above. 
  

			
	JACKSON FINANCIAL INC.
		
	By:	 	 /s/ Michael Falcon

		 	Name: Michael Falcon
		 	 Title:   Chief Executive Officer and
President

	
	PRUDENTIAL (US HOLDCO 1) LIMITED
		
	By:	 	 /s/ Kieran Devlin

		 	Name: Kieran Devlin
		 	 Title:   Director

	
	ATHENE LIFE RE LTD.
		
	By:	 	 /s/ Adam Laing

		 	Name: Adam Laing
		 	 Title:   SVP, Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]